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Abstract 
Osteoarthritis (OA), the most common form of arthritis, is estimated to be in the top 5 leading causes 
of disability worldwide. Yet OA incidence is estimated to keep growing partly due to the overall 
worldwide trend of increased obesity and ageing population. Cartilage erosion, a hallmark of OA, has 
its onset in the traumatic events caused by incorrect biomechanical loading of the joint and the 
consequent biological response. Currently we still poorly comprehend the molecular pathophysiology 
of preclinical and clinical symptomatic OA, which consequently results in no current available therapy 
to prevent OA progression. 
We hypothesize that innate immunity and its receptor, in particularly toll-like receptors (TLRs), 
could be major drivers of OA disease progression and onset. The process could be initiated as a 
proinflammatory reaction against extracellular matrix (ECM)-derived damage-associated molecular 
patterns (DAMPs). DAMPs accumulate in avascular articular cartilage as a result of traumatization and 
degeneration, leading directly at their source to a reactive chondrocyte-mediated and TLR-dependent 
production of proinflammatory and algogenic secondary mediators, which then cause a secondary 
synovitis with consequent joint pain. For this propose, we collected cartilage and isolated primary 
chondrocytes from a total of 27 OA patients. Synovial fluid was obtained from knee meniscectomy, 
total knee arthroplasty (TKA) due to OA, and rheumatoid arthritis (RA) patients generating a total of 
30 patient samples.  HEK (human embryonic kidney)-blue TLR4 reporter cell line, primary OA 
chondrocytes, and cartilage explants were used for functional studies. 
Our results confirmed that TLR1, TLR2 and TLR9 expression is present in healthy primary 
chondrocytes isolated from articular cartilage, and derived from chondroprogenitors. During our 
chondrogenesis differentiation studies initial high expression of TLR1, TLR2 and TLR9 was significantly 
reduced to baseline levels. 
We demonstrated that proinflammatory cytokine tumour necrosis factor alpha (TNF-α) is able 
to increase the expression of TLR2 in both healthy primary chondrocytes and mesenchymal stem cells 
(MSC) derived chondrocytes cultured for 21 days. TNF-α stimulation was demonstrated to induce 
cartilage degradation in de novo ECM matrix from pellet cultures of MSC-derived chondrocytes 
cultured for 21 days. This implicates TNF-α as an inducer of matrix degradation, with wide implications 
in the use of MSCs strategies in cartilage repair strategies for OA.  Our study also added further 
evidence of a role for TNF-α in TLR-innate immunity in the OA synovial joint. 
TLRs protein expression in cartilage between knee and first carpometacarpal (CMC-I) joints 
from OA patients was shown to be strikingly different. Our study demonstrated for the first time all 
TLRs being expressed at protein levels in articular cartilage from knee OA patients. Moreover, we 
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demonstrated that their expression is up-regulated in a cartilage zone-dependent fashion according 
to the histological progression of knee OA.  TLRs expression in cartilage from CMC-I OA patients was 
highly heterogeneous although it followed an expression pattern according to TLRs cellular 
organization. This indicates that TLR-mediated innate immune response between the two joints may 
be significantly different. 
Decorin (DCN), a known small structural proteoglycan with leucine-rich repeats (SLRP) ligand 
able to activate TLR2 and TLR4, was discovered in knee synovial fluid from OA and RA patients. We 
confirmed the ability of soluble DCN (sDCN) to activate to TLR4 signaling. However, the observed low 
and stable concentration levels across the studied groups mean that this may not be of clinical 
relevance in OA pathogenesis and the associated TLR-mediated inflammatory events. 
Biglycan (BGN), another known SLRP ligand able to activate TLR2 and TLR4, was discovered in 
knee synovial fluid from OA and RA patients. Interestingly, we discovered that soluble BGN (sBGN) is 
upregulated in synovial fluid from OA and RA patients. sBGN ability to activate TLR-innate immunity 
was confirmed to be essentially activated through TLR4 signaling by studies in articular chondrocytes 
and human HEK-blue TLR4 reporter cell line.  The sBGN stimulation lead to the upregulation and 
release of proinflammatory cytokines, matrix-degrading enzymes and the release of ECM degradation 
products. 
Overall, the results of this thesis demonstrate that TLRs are markedly present in articular 
cartilage from OA patients at different progression stages of the disease. The detection of BGN and 
DCN in synovial fluid, and their ability to activate TLR4-mediated proinflammatory cellular responses 
gives new knowledge of proinflammatory molecules present in the OA synovial joint. An enhanced 
molecular understanding of the triggering mechanisms by which TLRs are activated and regulated 
during OA progression stages may help find therapeutic options in the treatment of OA. 
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1. Introduction 
Osteoarthritis (OA), the most common form of arthritis, is estimated to be in the top 5 leading causes 
of disability in Finland and worldwide. Furthermore, OA incidence is estimated to keep growing partly 
due to the overall trend of increased obesity and aging population. By 2003, the annual cost of just 
hip joint replacement procedures in Finland was nearly 70 million € without taking into account post-
surgery rehabilitation (1). The current lack of treatment or prevention therapies coupled with an 
increasingly aging and overweight population lead to an estimated doubled number of people affected 
by OA disability at 2020. In Finland alone the incidence of total knee replacement surgeries among the 
baby boomer generation was increased by 130-fold during the short period of 1980-2006 (2). 
OA has historically been considered as a simple “wear and tear” joint disease with cumulative 
events over time and hence considered as mere a disease of the “old” (3).  Nowadays, however, OA is 
no longer considered as a simple wear and tear disease model, given that recent findings have clearly 
demonstrated that inflammatory molecular events are also major drivers of the disease progression. 
Cartilage erosion, the hallmark of OA, has its onset in the traumatic events caused by incorrect 
mechanical loading of the joint however its active degradation in mediated by proteolytic enzymes 
arising from “mild” inflammatory responses.  
OA synovium is also known to have increased infiltrates of inflammatory cells as seen in the well 
recognized classical pattern of rheumatoid arthritis (RA). Several inflammatory cytokines such as 
interleukin 1 beta (IL-1β), tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) are also 
increased in synovial fluid (SF), as a result of the crosstalk between synovium and cartilage tissues in 
OA patients (4). 
Thus, the modern views of OA, consider OA as disease of the whole joint which affects the 
synovial joint structures, including articular and meniscal cartilage degeneration and loss, subchondral 
bone changes, synovitis and altered nervous system (5). Moreover, the new OA pathogenesis 
paradigms are based on the crosstalk between mechanical-transduction and injury responses with 
ensuing inflammatory responses. Activation of the innate immune system, in particularly by Toll-like 
receptors (TLRs and the complement system, have been shown to be intrinsically related to a 
mechanic induction but also to a recognition of mechanical injury products (6). Despite increased 
research efforts and attention, we are only now starting to poorly comprehend the molecular 
pathophysiology mechanisms of preclinical and clinically symptomatic OA. Hence, effective preventive 
therapy or treatment for established OA is still lacking. 
This thesis studies TLRs at different differentiation stages of the chondroprogenitors to decipher 
the progenitor cells impact on OA cartilage repair strategies. TLRs are also studied during the 
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progression stages of OA and in different OA synovial joints, so that common and differential 
molecular players might be identified. We studied particularly the role of cartilage resident cells, the 
chondrocytes, and specifically the TLR-mediated inflammatory responses as measured by the 
production of cartilage breakdown enzymes, cytokines, and cartilage extracellular matrix (ECM) 
essential molecules. 
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2. Review of the Literature 
2.1. Epidemiology of OA  
The diagnosis of OA can be done clinically, radiographically and pathologically and therefore, the 
choice of diagnostic definition can significantly affect the prevalence estimates (7). Given the known 
incongruences in the descriptions of e.g. radiographic and clinical OA, other sensible and semi-
quantitative methods e.g. magnetic resonance imaging (MRI) and biomarkers are starting to be 
employed in epidemiological studies. In this thesis, the epidemiology section data will be based on the 
gold standard namely the radiographic diagnosis of OA and epidemiological studies using the 
radiographic diagnosis of OA of three main joints with high incidences, the hand, knee and hip. 
From as early as 1926 researchers have been studying the prevalence of OA. Their studies of 
pathological features of OA followed by systematic autopsy studies demonstrated an almost universal 
occurrence of cartilage damage in patients over 65 years of age (8). 
In contrast, with the first research methods applied to OA epidemiology, the current methods 
differ substantially. Nowadays OA epidemiological data are generated from population-based 
radiographic surveys.  
A common feature of all OA joints is the fact that radiographic OA prevalence rises 
progressively with age. To define radiographic knee and hand OA usually a radiographic Kellgren–
Lawrence (KL) score of 2 or higher grade in specific joints is used (9). The distal interphalangeal (DIP) 
joints, the proximal interphalangeal (PIP) joints, and the first carpometacarpal (CMC) joints or thumb 
base are the most commonly studied hand joints in comparison to the often spared 
metacarpophalangeal (MCP) joints. Radiographic hand OA in any hand joint or a selected subset of 
hand joint sites is usually defined as the criteria for case definition of hand OA (10). Population-based 
studies such as the Zoetermeer survey indicated that 75% of women aged 60–70 years presented with 
hand OA of their distal interphalangeal joint (DIP) joints. As early as in the age of 40, 10 to 20% of 
subjects had evidence of severe radiographic disease in their hands or feet (11). The Rotterdam study 
of a population-based cohort of individuals with 55 years or older reported that 67% of women and 
55% of men had radiographic OA, in at least one hand joint. Both hand and knee OA appear to be 
more frequent among women than men with a female-to-male ratio varying between 1.5 and 4.0 
among studies.  
For radiographic knee OA the Johnston County Osteoarthritis Project reported a prevalence 
of 28%  in men over 45 years old, a slight decrease in comparison with 37% observed in the first 
National Health and Nutrition Examination Survey (NHANES III)(12,13). Both studies found significant 
differences in the prevalence of radiographic knee OA between Caucasian, Afro-American and 
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Mexican American races. Interestingly the Beijing Osteoarthritis Study reported that Chinese women 
presented with a higher radiographic knee OA prevalence in comparison with white US women 
studied in the Framingham OA Study, 46% and 34% respectively. However, Chinese and white men 
did have an equal prevalence of radiographic knee OA (14). 
The overall prevalence of OA varies depending on the population studied. Nevertheless for 
hip OA the differences can be as small as 1% and up to 32% (15). Both NHANES III and Johnston County 
Osteoarthritis Project report a similar prevalence of 27-32% for radiographic hip OA among whites 
and blacks (16,17). In line with the knee OA prevalence, in hip OA Chinese women and men also have 
significantly lower rates, with a crude prevalence of ~1% (18). 
In line with prevalence studies, the incidence of radiographic OA also rises progressively with 
increasing age. In hand, knee and hip OA it is also important to consider the incidence of radiographic 
grade progression in OA patients. Interestingly, several studies have shown that the progression rates 
from a healthy baseline score to a radiographic OA score are significantly lower when compared to 
summary radiographic grade progression of an OA patient (19,20). 
2.2.  Risk Factors for OA: systemic and local risk factors 
Several risk factors for occurrence and progression of OA have been proposed, where many are in 
common to various OA joints while others may differ on the basis of the joint involved. Figure 1 
resumes the known risk factors associated with the three main joint types affected by OA. 
 
Figure 1. Risk factors of synovial joints radiographic OA. (Adapted from Felson et al. (21)). 
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2.2.1. Age and gender 
As discussed in the epidemiological section, age is undeniably a risk factor for OA, with OA being 
mainly diagnosed in patients over 60 years of age. The aging of the joint environment undermines the 
joint integrity making it susceptible to the development of OA. During aging, cartilage gets thinner, 
and cartilage homeostasis is impaired due to changes in the cellular function of chondrocytes (22). 
Chondrocyte density is decreased, cells becomes senescent and alter the balance between anabolic 
and catabolic functions. This undermines the chondrocyte response to growth factors and leads to 
alterations of cartilage extracellular matrix structure, therefore, compromising cartilage integrity 
(22,23). Age usually also influences the degree of physical activity leading to reduced muscle strength, 
which itself is a risk factor for OA. 
Gender also has a significant impact on the risk of developing OA. A recent systematic review 
of risk factors for OA analyzed 11 studies dealing with gender association to OA comprising more than 
28,000 individuals. The study corroborated the original studies in calculating that females have an odd 
ratio of 1.7 to develop OA as compared with males (24). Several factors may influence this e.g. gender 
distribution by work type or gender differences by sports activities, which are risk factors themselves. 
However other physiological gender-dependent factors may also play a role. It is known that estrogen 
receptors are present in joint tissues and that estrogen influences cartilage metabolism and bone (25). 
It is assumed that after menopause the hormone related changes and estrogen loss may enhance the 
development of OA.  Nevertheless, estrogen supplementation in the form of hormone replacement 
therapy has shown no benefit in preventing OA progression (24). 
2.2.2.  Obesity 
An overwhelming number of studies have found associations between obesity and OA. Studies have 
shown that obesity and overweight causes malalignment as well as extra loading of the lower limb 
joints i.e. hip, knee, ankle and feet (26,27). However, the association between OA and obesity is 
beyond the improper loading of the joints. Interestingly several studies have shown that obesity is 
also associated with upper limb e.g. hand OA, suggesting that metabolic factors may also be driving 
cartilage degradation and OA progression (28-31). Obesity also has significant detrimental effects on 
the behavioral factors which could lead to diminished physical activity and ensuing loss of protective 
muscle strength (32,33). Several studies have shown that by targeting such behavioral factors in obese 
patients a significant improvement is seen in pain and activity scores (34,35). 
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2.2.3.  Nutritional factors 
Vitamins with their given biological activities have made them subjects of study in OA disease.  That 
being said, it is also worth to note that there are a lot of conflicting reports in the literature about 
whether vitamins and other nutrient deficiencies are associated with OA disease. Nevertheless, 
vitamins role in OA pathogenesis therapy and treatment may one day be settled and prove to be 
important players. For this reasons, they are described in this section.  
A particular controversy lies around vitamin D, especially due to its wide range of implications 
including pain mechanisms and calcium uptake. Vitamin D deficiency has been implied as a risk and 
accelerating factor for OA (36). However, several studies reported no vitamin D effect (37,38). Vitamin 
D supplementation has also shown some positive effects in the prevention of progression of OA, albeit 
preventive effects have also been rejected in another study (39,40). Interestingly Vitamin D receptor 
(VDR) gene polymorphisms in association with OA have been observed, albeit conflicting results for 
knee OA patients have also been reported (41-43). VDR gene polymorphisms cause a change in VDR 
receptor activity and, therefore, alters the response to vitamin D, which then has implications for 
numerous factors e.g. calcium uptake. A recently published meta-analysis review of the literature has 
shown a small but statistically significant association of VDR and OA susceptibility in the Asian 
population, albeit no association with the European population (44). 
Vitamin E has also been a focus of interest. Low Vitamin E levels in SF of late OA patients were 
associated with severity of radiographic OA, while in the serum of late OA patients vitamin E was found 
to be increased (45,46). Nevertheless, in vitamin E supplementation studies no effect was observed 
regarding OA-based outcome of cartilage volume (47). 
Vitamin K deficiency has also been shown to be associated with hand and knee OA (48-50). 
Nevertheless, a three-year randomized clinical trial of vitamin K supplementation demonstrated no 
overall improvement in radiographic hand OA albeit a slight benefit in joint space narrowing was 
observed (51). 
Other antioxidants such as vitamin A, C and selenium, have been the focus of several OA 
studies. However, no significant associations with the levels of these antioxidants and OA have been 
found (52). 
2.2.4.  Physical activity 
Physical activity of people varies immensely and as expected the effects on the joints are also variable. 
Therefore, conflicting and varied reports on the influence of exercise on the progression of OA are 
more than anticipated. If relations exist, these may depend on the type of activity and stage of OA 
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disease. However, extreme patterns of physical activity are known to be risk factors. While casual 
marathon senior runners may not be at high risk of developing OA, professional runners have a high 
predilection for knee and hip OA even at early ages (53,54). Moreover, professionals with intense and 
repetitive manual labor such plumbers or miners have the predisposition to hand, knee and back OA 
at an early age (55,56). Further studies are still needed to decipher the influence of physical activity 
on the disease and on the risk of developing OA.  However, current measurements of physical activity 
and its patterns are imprecise and self-reported which inherently pose a challenge for further accurate 
data from this field. 
2.2.5.  Joint abnormalities, malalignments, and injuries 
A healthy joint with normal joint anatomy implies a correct physiological loading. However, when 
abnormalities occur the joint load can be significantly altered and this may have grave consequences 
for the joint health.  
Abnormal joint alignment of the knee has been associated with accelerated structural 
deterioration, the risk of medial and lateral progression, bone marrow lesions and rapid cartilage loss 
(57-59). 
Interestingly, abnormal muscle strength may also alter the joint alignment and, therefore, be 
a contributing factor for the development and progression of hand OA. High levels of grip strength can 
cause abnormal loading in hand joints leading to increased risk of OA in proximal hand joints (60). 
While the role of muscle strength for hand OA is clear, the same cannot be concluded for hip and knee 
OA. Albeit several and proper studies on the role of the muscle strength (e.g. quadriceps weakness) 
on hip and knee OA have been reported, findings are still discordant (59,61,62). The biggest limitations 
of these studies are whether muscle weakness is causal or the consequence of OA or caused by an 
OA-related risk factor e.g. obesity. 
Joint abnormalities such as hip dysplasia-associated malformations or hip cam impingement 
are known risk factors associated with hip OA, and it´s progression (63-65). Interestingly 
femoroacetabular impingement (FAI) incidence is higher in white women in comparison with Chinese 
(66). This reported incidences also suggest that such anatomic abnormalities may help explain the 
observed low incidence of hip OA in Chinese people in China and abroad in comparison with whites 
(67). 
2.2.6. Bone mineral density (BMD) 
Bone mineral density (BMD) changes is a known risk factor for OA. However, reports are again 
conflicting. Increased BMD has been shown to be a risk factor for the incidence of radiographic knee, 
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hip and hand OA (68-70). However, numerous studies have also shown an inverse correlation between 
BMD loss associated with radiographic progression of OA (71,72). Additionally, high BMD 
concentration levels are observed in knee cartilage of healthy subjects (73,74) It is also worth to 
mention that in animal models the use of drugs targeting bone resorption (anti-resorptive) may retard 
OA progression. Interestingly, the same strategy has provided encouraging results in the study of 
strontium ranelate efficacy in knee osteoarthritis trial (SEKOIA) (75). Taken together the literature 
seems to suggest that BMD loss may be a risk factor for radiographic progression of OA. Nevertheless, 
contradictory results remain and will endure as long as the underlying mechanism of this observation 
remains unclear (76). 
2.2.7.  Previous joint injury 
Significant damage to the structures of a joint is a risk factor for later development of OA in articular 
joints. Although some studies have demonstrated that Anterior cruciate ligament (ACL) surgical 
reconstruction may cause a moderate risk of developing knee OA, a recent systematic review showed 
that ACL reconstruction has no impact on radiographic progression of OA and, in fact, it “reduced” the 
risk of subsequent meniscus injuries (77). A more dramatic development was seen in patients with 
meniscal injury, who have a high risk of developing knee OA (78). Interestingly, surgical removal of 
torn meniscus seems to put patients at very high risk of developing knee OA (79). Therefore, indication 
of meniscectomy is a matter of concern in the research community with ongoing clinical trials 
addressing this issue. Furthermore, those who already have knee OA are at higher risk of radiographic 
progression of OA if meniscus tears occur (80). 
It is also worth to mention that a joint with an inherently low incidence of OA, such as the ankle, 
may present with an inevitable development of OA after a significant injury e.g. fracture (81). 
2.3.  OA pathogenesis & pathology 
2.3.1. The healthy synovial joint 
The synovial joints are the main joint type found in the body, and they are of tremendous importance 
for mobility, due to their unique characteristics, such as freedom of movement in many directions, 
provided with almost frictionless contact, allowing limbs to act smoothly. 
In order for the synovial joints to work effectively, they need stabilization mechanisms to avoid 
dislocations. Muscles surrounding the joint configuration are important stabilizing structures, and the 
efficient muscle action allows ligaments and fibrous capsule to guide the joint and limit the extension 
of motion. However, if timely concerted actions of the muscles are affected this can lead to excessive 
strain on the ligaments and capsule, leading at worst to their rupture (82).  
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Within the joint capsule, which defines the intra-articular space, is the synovial membrane. 
This membrane, composed of connective tissue and specialized cells, has two main functions: the 
provision of nutrients to the cells of the articular cartilage; and the production of lubricating fluid to 
ensure minimal friction that characterizes the synovial joints. The synovial membrane consists of two 
distinct layers: the synovial surface layer (also known as synovial lining), that secretes the SF, being in 
direct interface with the intra-articular cavity and the subintimal layer of connective tissue, which 
supports the synovial lining and the blood vessels that supply the membrane. The SF is, therefore, an 
essential element in maintaining joint integrity, as it provides nutrients necessary for cartilage matrix 
cells, and also lubricates the joint. The SF composition is crudely similar to plasma, but, in addition, it 
also contains hyaluronic acid (HA), a glycosaminoglycan, and lubricin, a mucinous glycoprotein. 
Together, these provide crucial contributions to the SF behaviour, due to their viscous and lubrication 
properties, respectively (83). 
The synovial joint is known to be innervated, to respond to several stimuli, such as chemical, 
mechanical and pain stimuli. The synovium, initially thought to be aneural as the articular cartilage, is 
actually innervated by efferent sympathetic nerves and by primary afferent nociceptors, that are 
specialized free nerve endings of primary afferent nerves (A-delta fibers and C fibers)(84). Together 
these are known to respond to stimuli such as to chemical and mechanical and consequently mediate 
the vasculature response. There is also evidence of pain response (84). 
In the meniscus, nociceptors and mechanoreceptors are widely distributed, to immediately 
signal mechanical realignment when extreme pressure or tension are sensed, as a consequence of 
misalignment over the tissue (of the meniscus)(85). Moreover, the innervation at the meniscus also 
generates prociceptive information for correct coordinated movement, velocity and direction. 
Furthermore, the meniscus high level of innervation, angiogenesis and nerve growth has led some to 
propose its contribution to the triggering of threshold levels of pain sensitivity in OA knee (86). Given 
the fact that articular cartilage plays a significant role in the synovial joint and is also intrinsically 
related to OA, detailed analysis of its characteristics will be discussed in the next section. 
2.3.1.1.  Articular cartilage biology 
Different types of cartilage tissue are present at various sites throughout the body. Cartilage can be 
classified by histological analysis of its molecular composition into: elastic, hyaline and 
fibrocartilaginous. Of these cartilage types, hyaline cartilage is the most common cartilage and is 
associated with the skeletal system. Articular cartilage is attributed as hyaline cartilage, and can be 
divided into three individual zones: the superficial zone, the middle zone (can be also divided into 
subgroups: the transitional zone, the radial zone), the deep zone, and the calcified cartilage zone 
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where  the interface with the subchondral bone lies (87) (Figure 2). These individual zones are 
characterized as having different organized structures of collagen network and as well as different 
molecular types and levels of proteoglycans, and, therefore, distinct anisotropy and polarity can be 
observed. Table 1 resumes the features mainly observed in the different zones.  
Table 1 - Definition of structures composing the different articular cartilage zones. 
Term Definition 
Superficial zone 
Cartilage zone at joint surface. Collagen fibers are aligned parallel to 
surface. Chondrocytes, elongated and flattened, are aligned parallel 
to collagen fibres and to joint surface 
Middle Zone 
Zone subjacent to superficial zone. Collagen fibers are aligned 
intermediately between superficial and deep zone alignments. 
Chondrocytes present in groups (chondrons) aligned parallel to 
collagen fibers. 
Deep zone 
Zone subjacent to mid zone and above calcified cartilage. Collagen 
fibres are aligned predominantly perpendicular to joint surface. 
Chondrocytes within chondrons are aligned parallel to collagen fibers 
and perpendicular to joint surface. 
Tidemark 
Zone of increased calcification at border of uncalcified and calcified 
cartilage. 
Calcified cartilage 
Calcified cartilage matrix. Collagen fibres and chondrocytes are 
aligned similar to deep zone cartilage. 
Articular bone plate 
Bone subjacent to articular cartilage. Collagen fibres aligned 
predominantly parallel to articular surface. 
Adapted from Pritzker et al. (87). 
As previously described, throughout the cartilage zones there are different collagen molecular 
types. Of these different types of collagens, type II is the main component in healthy articular cartilage. 
However, collagens III, VI, IX, XI, XII and XIV also contribute, although with a minor proportion, to the 
mature cartilage matrix (88). 
Among the proteoglycans present in cartilage, aggrecan is the most abundant. Aggrecan is a 
large chondroitin sulfate proteoglycan, which due to its molecular structure produces a rigid, 
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reversibly deformable gel that resists compression. Besides aggrecan and HA other proteoglycans are 
also found in cartilage, examples are: fibromodulin, lumican, epiphycan, decorin, biglycan, perlecan, 
syndecans and glypican (89). Proteoglycans are composed of a core protein synthesized by 
endoplasmic reticulum, attached to several glycosaminoglycans (GAGs) abundant in sulfate and 
carboxyl groups. These groups, due to their negative charges (hydrophilic), drive the attraction of 
water molecules in large amounts, which then accounts for the resilient nature of cartilage (89). 
The chondrocytes present in cartilage are disposed in zonal stratification and enclosed in the 
arcade-like network of collagens fibrils, to which proteoglycans are attached. This specialized spatial 
organization of the articular cartilage and the enclosed chondrocytes results from the complex 
endochondral ossification process that occurs during embryogenesis (90). The endochondral 
ossification has two centers of ossification; the primary center ossification that occurs at the diaphysis 
and the later secondary ossification center occurring at the epiphysis. Figure 2 presents schematically 
the cartilage structure across the different cartilage zones. 
 
Figure 2. Histological Illustration is showing the features of healthy human articular cartilage and subchondral 
bone. At the superficial zone chondrocytes are small and flattened, which are orientated parallel to the joint 
surface. Small and medium-sized collagen fibrils are aligned parallel to the cartilage surface. In the middle zone 
chondrocytes become more rounded and are randomly oriented. The collagen fibrils start to become orientated 
towards a vertical direction relative to the cartilage surface. In the deep zone, chondrocytes are clustered in 
columns know as complex chondrons where they share pericellular matrix. At this point, the large collagen fibrils 
are aligned almost vertically to the cartilage surface. 
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As earlier stated, chondrogenesis is at the onset of the endochondral ossification process. It 
relies on synchronized events that allow mesenchymal cell recruitment and migration, proliferation 
and later condensation of mesenchymal chondroprogenitors cells, allowing them to establish the 
formation of pre-cartilaginous condensations. During chondroprogenitors differentiation into 
chondrocyte cells, the ECM composition undergoes changes. During chondroprogenitors 
differentiation, initial expression of collagen type I is reduced giving its place for chondrocytes to start 
producing collagen II, IX and XI, proteoglycans such as aggrecan, and link protein and Gla protein (88).  
This composition will be then a remnant of the initial cartilage formation, which will be largely retained 
in adult articular cartilage. In the sites where embryonic cartilage is replaced by bone, chondrocytes 
differentiate further in a process called hypertrophic differentiation during which they start secreting 
collagen X. As bone formation starts to occur, cartilage is vascularized from the perichondrium. As a 
result ECM mineralization occurs, due not only to the hypertrophic chondrocytes but also later, as the 
formation of the bone matrix progresses, to the coordinated action of mineralizing osteoblasts and 
bone resorbing osteoclasts. These migrate to help to remodel cartilage into mature bone (91). 
In summary, articular cartilage is an avascular and aneural connective tissue made of 
chondrocytes entrapped in lacunas by an arcade-like network of fibrils of collagens and proteoglycans. 
Together this organized network of molecules will be passed to the orientation and shape of 
chondrons (basic cellular structure consisting of one or more chondrocytes surrounded by pericellular 
matrix). Moreover, since it is avascular, cartilage nutrition occurs through diffusion. The predominant 
source of diffusion is the SF. To nutrients reach the chondrocytes residing in the cartilage, they must 
pass through a double diffusion system, the synovial membrane and the cartilage matrix (92). This 
diffusion mechanism is helped by the pumping action of its compression or by the flexion of the elastic 
cartilage (93). 
2.3.2. Preclinical OA 
By the time OA is clinically established with observed radiographic joint changes, the joint tissue level 
of structural and degenerative changes as seen in cartilage, imply almost irreversible damage. Since 
OA treatment is symptomatically driven, this may help to explain why current treatments are not 
delaying OA arthroplasties. Currently, many researchers in the field believe that if any OA treatment 
is going to be successful, it should be started in the earliest phase of the disease before the clinical 
diagnosis, in other words, in preclinical OA. Until nowadays OA clinical diagnostics has relied on 
observed radiographic changes. However, OA joint abnormalities undetectable by X-ray can be 
observed using more sensitive imaging techniques such as MRI or ultrasound (94,95). 
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While the use of more advanced imaging techniques may one day change the clinical 
threshold for OA diagnosis, OA associated symptoms cannot be used as diagnostic tool given that 
symptoms increase, decrease, and disappear during preclinical and clinical phases of OA, and may also 
be related to multiple causes. Therefore, the focus of this thesis section is on preclinical OA, the early 
stages of the disease, which precede OA joint-related structural changes being detectable by imaging 
techniques. 
As discussed earlier, joint trauma is a known risk factor for OA, hence the categorization of 
post-traumatic OA given the apparent causes for its development (96). Therefore, studying the disease 
development from trauma to clinical diagnostic offers an exceptional insight into the mechanism of 
the disease and apparently corroborates the existence of preclinical OA phase within a defined time. 
Several longitudinal studies following a traumatic event of a joint have undeniably shown a persistent 
molecular preclinical disease phase portrayed by several protein biomarkers and RNAs at increased 
concentrations (97-102). Many of these protein biomarkers are fragment products of essential 
cartilage macromolecules e.g. aggrecan and collagen type II and are critical to the biomechanical 
properties of the unique structure of articular cartilage (103). Such damaging alteration of native 
cartilage structure is thought to be naturally irreparable and precursor of the development of post-
traumatic radiographic OA. Moreover, many of these released fragments e.g. tenascin-c can also 
activate wound healing mechanisms which if left unbalanced can cause prolonged inflammation in 
resident chondrocytes and synovial cells (104,105). This in turn also make such biomarkers potential 
molecular players in OA pathogenesis. 
In comparison with post-traumatic OA, tracking primary idiopathic OA development within a 
certain time frame is much more challenging. However, some studies have strikingly demonstrated 
that biomarkers, such as a combination of cartilage oligomeric protein (COMP) and hyaluronic acid 
(HA), could predict the development of joint radiographic abnormalities in knee and hip joints a few 
years earlier (106-108). Interestingly, preclinical OA existence seems to be further corroborated by 
cadaveric studies which have shown an incidence of 69% and 86% of articular cartilage lesions 
(radiographically undetected and asymptomatic) in cadaveric knees and hands, respectively (109,110). 
Together these studies have shown that molecular alterations do occur before radiographic OA, and 
thus, further support the existence of a preclinical phase of OA. 
2.3.3.  OA pathology 
The progressive histological changes in articular cartilage in OA are well recognized. Macroscopically, 
normal hyaline articular cartilage is sleek and pale cream to yellow in colour. In OA, the cartilage seems 
discoloured, soft, and cracked with the underlying subchondral bone exposed at end stages. Such 
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changes may be observed and graded radiographically as well as further studied in detail, 
histologically. In early OA, cartilage physical or proteolytic disruption of the type II collagen network 
results in increased water content and proteoglycan swelling of articular cartilage leading to increased 
cartilage volume (111). As OA progresses and the expression and activity of cartilage matrix-degrading 
enzymes increase, the cartilage proteoglycan content is reduced substantially. Later on, direct physical 
forces on the weakened cartilage cause surface matrix fibrillation, cracks within the superficial layer 
of the articular cartilage that run parallel to the surface. These cracks expand, following the collagen 
fibers orientation within the middle and deep cartilage zones. The ongoing mechanical traumas cause 
fissure branches to propagate, and this, together with the continued proteolytic activity, results in 
continued cartilage loss. In contrast to the reduction in the volume of noncalcified articular cartilage, 
the thickness of the calcified cartilage zone will increase. At this stage, microcracks appear in calcified 
cartilage which may extend into subchondral bone lining causing bone remodelling. The interface zone 
between non-calcified and calcified cartilage, known as tidemark is seen as duplicated or multiplied 
reflecting the process of the cartilage thinning (87). The intimately related subchondral bone structure 
is altered, thickened, and bone sclerosis occurs. The failed remodelling of subchondral bone 
microfractures leads to the microfracture space to be filled with non-native fibrocartilaginous tissue 
derived from local joint stem cells. In OA late stages, cartilage-naked subchondral bone is covered with 
a fibrocartilaginous tissue arising from stem cell differentiation (87).  
2.3.4.  Grading of osteoarthritic cartilage alterations 
Traditional diagnostic criteria commonly used in many other diseases are difficult to apply for OA 
classification, mostly due to the heterogeneity of the causes of disease and its symptoms. This task is 
even more difficult to implement for the classification of disease progression. Along with the 
progression of OA cartilage degeneration is increased. Although other joint tissues are also involved 
in OA, cartilage has traditionally been used to score OA severity. 
Several scoring systems exist to estimate the progression of the disease process of OA, based 
on imaging techniques commonly applied to OA, i.e. radiological, MRI and ultrasound (112). These 
systems such as the Kellgren-Lawrence system, and others, enable the relative description of visible 
features through OA stage progression. However, these systems use radiographic evidence and other 
macroscopic observations. As tissues changes occur prior to visible lesions, this leads to the necessity 
of clearly identifying underlying molecular events in order to better understand the role of cartilage 
pathological features, characteristics of OA biological activity and progression. Histological evaluation 
enables researchers to observe at the microscopic scale the cellular/molecular events intrinsically 
related to the cartilage alterations that occur in OA progression. 
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For the histopathological assessment of OA, there are currently two dominating aproaches: 
the one proposed by Mankin et al. and the one from Pritzker et al. which is endorsed by the 
Osteoarthritis Research Society International (OARSI) (87,113). Both grading systems have high 
reliability, reproducibility and variability (114). However, the OARSI grading arose from the need to 
address specific issues not covered by the Mankin based systems, such as severity of cartilage damage 
and percentage of area affected.  
The OARSI grading system defines grade as the OA depth progression into cartilage, assuming 
that OA involvement of deeper cartilage layers reflects a more advanced disease and, therefore, is in 
line with the pathological cartilage features. The grading methodology of the OARSI system is 
summarized in Table 2. Description of cartilage zones natural architecture can be found in Table 1. 
Histological staining features used in the OARSI system to grade the OA cartilage degradation are 
represented in Figure 3. 
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Table 2. The OARSI grading methodology for OA cartilage histopathology grade assessment. 
Grade Associated feature 
Grade 0: Surface and 
morphology 
Intact, uninvolved cartilage 
Grade 1: Surface Intact 
Matrix: superficial zone intact, edema and/or fibrillation 
Cells: proliferation (clusters), hypertrophy, Reaction must be 
more than superficial fibrillation only 
Grade 2: Surface 
discontinuity 
As previous 
+ Discontinuity at superficial zone 
+/- Cationic stain matrix depletion 
(Safranin-O or Toluidine Blue) upper 1/3rd of cartilage 
(mid zone) 
+/- Disorientation of chondron columns 
Grade 3: Vertical fissures 
As previous 
+/- Cationic stain depletion (Safranin-O or Toluidine 
Blue) into lower 2/3rd of cartilage (deep zone) 
+/- New collagen formation (polarized light microscopy, Picro 
Sirius Red stain) 
Grade 4: Erosion 
As previous  
Cartilage matrix loss, cyst formation within cartilage matrix 
Excavation: matrix loss superficial layer and mid zone 
Grade 5: Denudation 
Surface is sclerotic bone or reparative tissue including 
fibrocartilage 
Grade 6: Deformation 
Bone remodeling. Deformation of articular surface contour 
(more than one osteophyte formation only) 
Includes: microfracture and repair 
Adapted from Pritzker et al. (87) 
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Figure 3. Toluidine blue staining of OARSI-graded osteoarthritis (OA) samples, grades G1-G4.5. Surface 
(tangential, gliding), middle (transient), deep (radial) zones, tidemark (between cartilage and calcified cartilage) 
and subchondral bone are marked. 
2.3.5. Articular cartilage and chondrocytes: the OA phenotype 
As described elsewhere articular cartilage is a unique highly specialized tissue with one of a kind 
biomechanical properties, and solely populated by one cell type in an avascular, alymphatic and 
aneural microenvironment. These unique characteristics make it challenging for the cartilage to be 
naturally regenerated and also reconstructed or engineered. 
Disruption of the collagen network and proteoglycan by matrix-degrading proteases is a major 
threat to cartilage matrix integrity. Such cleavage and degradation of matrix molecular components is 
harmful per se but also compromises the structure of the residing supramolecular proteins which give 
cartilage so unique properties. This enzymatical degradation of articular cartilage leads to the erosion 
of pericellular matrix and eventually the interterritorial matrix which will ultimately compromise and 
alter cartilage biomechanical properties leading to the destruction of articular cartilage (115,116). 
To date, we have extensive knowledge about the degradation processes of the two major 
components of articular cartilage: the collagen network and the rooted proteoglycans. Loss of 
aggrecan and its bounded cationic proteoglycans is one of the most striking features of early stages of 
cartilage degeneration (87). While collagen content is not as heavily reduced, its network, in turn, is 
highly disrupted making it also a fundamental feature of cartilage osteoarthritic changes. Yet the two 
have reciprocal effects i.e. collagen network degradation leads to loss of GAGs and GAGs loss alter 
biomechanical properties leading to joint overload which will inflict further damage to the collagen 
network structure.  
As mentioned before the cartilage degradation process is prominent in the pericellular matrix 
and superficial zone. At this zone and throughout the osteoarthritic cartilage abnormal levels of many 
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metalloproteinases including matrix metalloproteinases (MMPs), as well as members of the ADAM (a 
disintegrin and metalloproteinase) and ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin type 1 motif) families are observed and undeniably contribute to the increased 
matrix degradation in OA cartilage (117). These enzymes play a significant role in cartilage 
degradation. However, attempts to identify the most crucial protease have been unsuccessful. This 
may imply that all of them are vital and that treatment strategies should target upstream regulators. 
Collagen type II is the primary collagen type present in articular cartilage, which forms the 
collagen network necessary for cartilage stiffness. Therefore, proteases degrading such important 
molecule deserve significant attention. MMP-1 degrades collagen type II efficiently. It is upregulated 
in cartilage and SF from OA patients, its gene polymorphism has also been shown to be associated 
with OA in a population study, and MMP1 expression is typically up-regulated in chondrocyte induced-
inflammation (118-120). 
With the strongest OA cartilage staining features of all MMPs, MMP-3 is another important 
protease (121). MMP-3 also mediates the activation of other collagenases e.g. MMP-1 and MMP-13 
(122). Mice models have shown that MMP-3 KO mice are protected against site-specific cleavage of 
collagen and aggrecan, but at the same time may produce a severe OA type when surgically induced 
(123,124). Another MMP shown to be associated with OA is MMP-9, a collagenase, which has been 
proved to be protective in OA mice models (125). 
Among MMPs, MMP-13 has been the subject of most intensive attention given its extensive 
collagenase activity. MMP-13 is expressed by chondrocytes, and it hydrolyses type-II collagen more 
efficiently than others (126). MMP-13 has been shown to be upregulated in OA cartilage (127). 
Together MMP-1,-2,-3,-7,-9, and -13 also are able to cleave aggrecan at the Asn341~Phe342 
bond, however it has been shown that the majority of aggrecan neoepitopes present in OA are made 
at Glu373~Ala374 bond specific for ADAMTS-4 and ADAMTS-5 activity (128,129). The significant presence 
of Glu373~Ala374 neoepitopes gives further importance to the role of ADAMTS-4 and ADAMTS-5. These 
aggrecanases are typically upregulated in chondrocyte induced-inflammation as well as in human OA 
cartilage (119,130). Mice models have also shown that ADAMTS-4 and -5 mice KO with prevented 
cleavage of Glu373~Ala374 neoepitope are protective for cartilage destruction in surgically induced OA 
and antigen-induced arthritis (129,131,132). 
Another class of major “players” are cathepsins which originate from the lysosomal 
compartment. Of the existing ones, cathepsin K (CTSK) deserve the most attention. It has been shown 
to be upregulated in cartilage, SF and serum from OA patients. Cathepsin-k activity is pH dependent, 
and it seems to give it further importance since OA cartilage becomes progressively acidic as the 
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disease progresses (133). Therefore it is not surprising that recent studies have been able to 
demonstrate increased activity of cathepsin-k in OA cartilage and in chondrocytes (134,135). 
The majority of these proteases localized in articular cartilage are produced by local resident 
chondrocytes, the only cell type present in articular cartilage. They are, therefore, central “players” in 
tissue homeostasis, acting in concert to preserve the structural integrity of ECM in articular cartilage. 
Not only these cells play a role in matrix catabolism, but they do also actively regulate the matrix 
anabolism. In healthy cartilage, chondrocytes synthesize low amounts of new ECM molecules to 
replace damaged molecules, meanwhile, in OA their anabolic activity is clearly altered. 
In chondrocyte-induced inflammation and OA chondrocytes phenotypic studies, the catabolic 
events are not sufficiently counterbalanced by the anabolic events given the insufficient synthesis of 
cartilage matrix molecules e.g. collagen type II, V and aggrecan (119,136). Such imbalance leads to 
failure to compensate the total matrix cartilage damage induced in the local synovial joint. 
2.3.6.  OA pathogenesis: a modern view 
As earlier described, clinical OA is preceded by a preclinical stage which together with the presence of 
risk factors and/or other pathological processes cause the disease to enter in a state of radiographic 
OA. Several of these risk factors are considered by some to be the main single pathological event 
which may explain OA pathogenesis. However, along the research history in this field, neither a single 
nor two risk factors could alone explain OA pathogenesis. The emerging current view in the field is 
that such risk factors and triggering mechanisms act together in driving the disease into the 
radiographic stage. 
As discussed in previous sections, the presence of preclinical stage OA demonstrates that OA 
is an apparently active disease process. As cartilage is subject to considerable mechanical impact, 
compression, tensile and shear loading this may cause micro and or major trauma to the cartilage. 
Moreover, such mechanical insults can be mechanically transduced by mechanosensors present in 
resident chondrocytes which then may alter their normal phenotype and activate certain matrix 
degrading enzymes (137). The generated fragments may then accumulate to increase levels during 
time, given the cartilage alymphatic, avascular and aneural characteristics and the nonlinear and size 
dependent molecular clearance rate of the synovial membrane (138,139). As the cartilage 
degenerates, matrix molecules and fragments are released and accumulated leading to the 
propagation of inflammation through the activation of innate immune response by damage associated 
molecular patterns (DAMPs) (140). Such occurrence of inflammatory and immune reactions, clinically 
presenting as inflammatory flares, are unmistakable points for OA diagnosis. While inflammation as 
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the principal triggering mechanisms or a primary driver is still very much debated, inflammatory 
pathways are undoubtedly involved in the pathogenesis of OA (6,141,142).  
Metabolism and associated cascades of chondrocyte and fibroblast-like synoviocytes (FLS) can 
be altered by inflammatory factors such IL-1 and IL-6 which can lead to a phenotypic change of 
chondrocytes towards an inflammatory type i.e. becoming hypertrophic, destructing cartilage and 
initiate bone remodelling (143). Interestingly, chondrocyte can also be sensitized to inflammatory 
signals. It was shown in mice that upregulation of syndecan-4 during induced OA progression mediates 
the response to IL-1, by altering the secretion of several collagenases and aggrecanases (144). Not 
only inflammatory signalling cascades are triggered by cytokines, but inflammatory pathways 
mediated by complement, metabolic and innate immune system are also present.  
As we know today, the innate immune system is an intrinsic part in the inflammatory cycle of 
OA (145,146). The key point of innate immune systems role in OA lies in how it reacts to the 
mechanical, physiological and biological changes in the joint over time. In contrast to the adaptive 
immune system, innate immunity plays an essential role not only in  host defense against microbial 
agents but also in modulation of tissue homeostasis by recognizing distinct pathogen-associated 
molecular patterns (PAMPs) and DAMPs, respectively, by pattern recognition receptors (PRR), such as 
Toll-like receptors (TLR) and NOD-like receptors (NLR) (147).  Therefore, cartilage matrix degradation 
products derived either from trauma, microtrauma (from repetitive overuse), or normal aging 
degeneration lead to the release of DAMPs that may then activate a local innate immune system 
reaction (148,149). The activation of these inflammatory pathways induces chondrocytes signalling 
changes which lead to the upregulation of cartilage matrix degrading proteases such as MMP-1, MMP-
3, MMP-13, and ADAMTS aggrecanases while also downregulating aggrecan and collagen type II, a 
pattern generally seen in the OA chondrocytic phenotype. Such gene expression patterns within 
articular chondrocytes are mediated via multiple intracellular pathways including also the 
macrophage adhesion molecule (MAC) and Mitogen-activated protein (MAP) kinases and nuclear 
factor-κB pathways (NF-kB) (150,151). 
As mentioned earlier, inflammation occurs in local synovial joint during OA, and, therefore, 
cartilage and local chondrocytes are not solo “players” in OA pathogenesis. Besides clinical relevance, 
synovial inflammation is also part of the OA pathogenic mechanisms. In contrast to RA, synovial 
inflammation in OA is thought to be secondary to the release of cartilage degradation products 
including DAMPs (140).  OA synovium has increased FLS activation, proliferation and infiltration of 
inflammatory cells consisting of macrophages and lymphocytes (152). Such events may, in fact, 
represent reactive changes as a response to the overwhelming need of synovial fluid clearance flooded 
in cartilage debris and DAMPs. Studies have also shown that altered molecular composition does also 
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change the SF viscosity among other mechanical properties essential for synovial joint mechanical 
function (153,154). Therefore, when synovial alterations occur such as in inflammation and 
hyperplasia, the permeability of the membrane is also altered (139). Different permeability may help 
explain why systemic markers, e.g. HA, which are increased in local OA joint, may then be found in 
serum from OA patients (155). Activated FLS are able to secrete not only matrix-degrading proteases 
such as collagenases and aggrecanases but also catabolic cytokines and growth factors (e.g., IL-1, TNF-
α) as well as ROS/NOS which will further cross-talk with ongoing inflammatory and catabolic signaling 
pathways active in chondrocytes. The interplay of mechanical traumas, environmental factors, 
potentiated by risk factors and genetics, ensued by an inflammation perhaps driven by innate immune 
response and impaired cartilage repair, is one of the latest modern views of the OA pathogenesis 
theory (145). Figure 4 represents the unifying model of OA pathogenesis schematically.  
 
 
Figure 4. Unifying model of OA pathogenesis. (Reprinted with permission from Rheumatology 6th Edition, 
Volume 1, Marc C. Hochberg, Alan J. Silman, Josef S. Smolen, Michael E. Weinblatt and Michael H. Weisman, 
Preclinical osteoarthritis, 1570-71, Copyright Mosby Elsevier, 2015. 
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2.4. Toll-like receptors  
As previously mentioned, innate immunity may play a significant role in OA pathogenesis, therefore 
also PRRs and, in particular, TLRs may have an important role given recent findings of their presence 
in both chondrocytes and chondroprogenitor cells (156-158). 
2.4.1. Toll receptor 
After 10 years of the proposed theory of pattern recognition of pathogens, the first human PRR was 
discovered. This work had roots in earlier discovery in the fruit fly Drosophila (159). Although 
Drosophila had provided ground breaking research for human genetic developmental studies when it 
came to human immunity, drosophila was considered less significant for immunological studies given 
its lack of adaptive immune response (160). Interestingly in one of those gene mutations 
developmental studies eventually a gene for TLR was mutated, at the time baptized Toll, TLR was 
mutated leading to strange looking drosophilas. Cloning efforts of such gene demonstrated that it 
encoded a membrane receptor (161). 
Later on, functional studies demonstrated that loss-of-function Toll mutations in Drosophila 
increase the susceptibility for fungal infection while gain-of-function mutations may have been more 
resistant to fungal infection given the increase production of antifungal peptide “drosomycin” (162). 
By comparing Toll mutation to other gene mutations, researchers realized the importance of Toll 
receptor in fungal infections and as part of innate immunity response in Drosophila. Later on by using 
the amino acid sequence of Toll, researcher were able to find the first human TLRs (163,164). 
2.4.2. Structure and function 
TLRs are typical type I integral membrane receptors composed of a ligand recognition ectodomain, a 
single transmembrane helix, and a cytoplasmic signaling domain projecting from the inside part of the 
membrane (165).Toll IL-1 Receptor (TIR) domains are the signalling domain of TLR. The name was 
given since they are homologues to the IL-1R family members signalling domains (166). Interestingly 
TIR domains homologs are also present in plant proteins and nematode C. Elegans conferring them 
therefore also pathogen resistance. Such phylogenetic relations indicate that the TIR domain and TLR 
have an ancient evolutionary origin in host defense mechanisms (167-169). 
As previously mentioned TLRs play a critical role in the activation of innate host defense, 
especially against infections by recognizing PAMPs. PAMP-TLR ligand recognition leads to the initiation 
of cellular activation. Currently, 11 TLR gene members have been discovered, numbered from 1 to 11, 
of which the first 10 are also functional in humans, albeit to date no natural ligand to TLR10 is known. 
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TLR1, TRL2, TLR4, TLR5, TLR6 and TLR10 recognize microbial surface patterns and are therefore located 
on the cell membrane surface to enable an immediate response. Some other TLRs, such as TLR3, TLR7, 
TLR8 and TLR9, are expressed in the endosomes or phagosomes inner membranes to allow contact 
with internal microbial structures revealed upon microbial degradation/lyses, such as double and 
single stranded RNA and DNA (170). 
TLR-mediated recognition leads to host responses in the form of de novo expression of genes, 
such as inflammatory cytokines tumour necrosis factor (TNF)-α, IL-1, IL-6, IL-8 and IL-12 and cell-
membrane bound co-stimulatory molecules, such as intercellular adhesion molecule-1 (ICAM-1) and 
its counterpart lymphocyte function-associated antigen-1 (LFA-1) (171).  
2.4.3. TLR signalling 
The surface membrane and endosomal TLRs share similar ectodomain sequences, which is in sharp 
contrast to the different ligands they bind. By having distinct residues present in the ectodomains of 
the various TLRs is a way of discriminating between ligands. At the ectodomains of TLRs lie the leucine-
rich repeat modules each of them composed of 20–30 amino acids with the consensus sequence 
LxxLxLxxN. By having different amino acids inserts within the modules, this leads to variations which 
allow TLR-ligand interaction (172). Nevertheless, such amino acids differences and TLR 
heterodimerization are not able to fully recognize all the existing TLR ligands. In order for this to occur 
specific accessory proteins and co-factors are necessary. Co-factors lipopolysaccharide (LPS)-binding 
protein (LBP), cluster of differentiation 14 and 36 (CD-14; CD-36), myeloid differentiation factor-2 
(MD-2), TRIL are some of the currently known existing TLR homo- and heterodimers helping to 
recognize the broad range of TLR ligands (173). A classic example of co-factor importance is LPS 
recognition by TLR4 homodimer, where LPS is initially bound to the LBP. This is followed by LBP-LPS 
complex delivery to CD14, either to its soluble form or cell surface form, which splits LPS into 
monomeric molecules and presents them to the TLR4 in complex with MD2 (174). Ligand-induced 
receptor homo- or heterodimerization, leads to the dimerization of the cytoplasmic signaling domains 
of TLRs. The majority of TLRs form homodimers, however, TLR2 is able to form heterophilic dimers 
with TLR1 or TLR6, and TLR4 to form and heterodimer with TLR6 (175,176). Such TIR-TIR dimer 
complexes trigger the signaling downstream, through recruitment of specific adaptor molecules. To 
date five distinct adaptors are known: myeloid differentiation factor 88 (MyD88), MyD88-adaptor like 
(Mal), TIR domain-containing adaptor inducing IFN-beta (TRIF), TRIF-related adaptor molecule 
(TRAM), and sterile alpha and HEAT-Armadillo motifs (SARM) (172). With the exception of TLR3, which 
is exclusively TRIF dependent, all TLRs depend at least in part on the MyD88-pathway for their full 
signalling activity. IL-1R-associated kinase-1 (IRAK1), IRAK-2, TNF receptor-associated factor 6 (TRAF6) 
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and mitogen-associated protein kinase (MAPK) are some of the known accessory molecules to be 
involved that ultimately will lead to triggering of the transcription factor NF-kB. By being transported 
via the IkB kinase (IKK) complex it will ultimately activate the production of proinflammatory 
cytokines. As mentioned earlier TLR3 does not signal through the MyD88 (due to mutation in amino 
acid chain in position 712 to histidine), instead it uses the TRIF pathway. TRIF associates with TRAF3 
and TRAF6, but also with receptor-interacting proteins, that will activate downstream the NF-kB and 
MAPKs, resulting in the production of interferon (IFN). TLR4 can also signal through this pathway, but 
requires the adaptor TRAM under some conditions (177). Table 3 resumes some of the currently well 
described existent PAMPs and DAMP triggering TLRs activation. 
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Table 3. PAMPs, DAMPs and danger signals able to trigger TLRs signalling activation. (Data adapted 
from (178,179)). 
TLRs Exogenous ligands Endogenous ligand 
TLR1 TLR1/2  bacterial triacyl lipopeptides, OSP of 
borrelia spp. 
___ 
TLR2 TLR1/2  bacterial triacyl lipopeptides bacterial 
peptidoglycan, LAM, LTA, GXM, Zymosan, TLR1/2 
Pam3CSK4, viral envelope glycoproteins, APO CIII 
HSPs, Biglycan, Hyaluronan, Monosodium 
urate crystals, Versican 
TLR3 ssRNA, dsRNA, TLR3/9 CMV, Stahmin ssRNA 
TLR4 LPS, MMTV, RSV fusion protein, LPA, Fibronectin, 
viral envelope glycoproteins, Heparin sulphate, 
Paclitaxel, BCG 
Biglycan, Β-defensin, decorin, Fibrinogen, 
Fibronectin isoforms,  Heparan, HSPs, 
Hyaluronan sulphate, Tenascin-C, S100-
A4, S100-A8/A9, Resistin, Surfactant 
protein A, Uric acid 
TLR5 Bacterial Flagellin _____ 
TLR6 TLR2/6 di-acyl-lipopeptides, peptidoglycan from 
gram positive bacteria, Zymozan 
___ 
TLR7 ssRNA, imidazoquinoline, bropirimine, loxoribine Self RNA, siRNA 
TLR8 Bacterial ssRNA Self RNA, siRNA human myosin 
TLR9 Hypo and unmethylated CpG motifs in microbial 
DNA, HSV-2 
Self DNA 
TLR10 unknown _____ 
CMV - cytomegalovirus; dsRNA - double-stranded ; siRNA – small interfering RNA; ssRNA - single stranded; LPS 
-lipopolysaccharide; MMTV - murine mammary tumor virus ; RSV- respiratory syncytial virus; LTA - lipoteichoic 
acid; HSV - herpes simplex virus; HA  -hyaluronan; OSP - outer surface protein; BCG- Bacillus Calmette-Guerin, 
LAM- lipoarabinomannan; EDN - eosinophil-derived neurotoxin; Pam3CSK4- synthetic triacylated lipopeptide; 
LTA - lymphotoxin alpha; APO - Apolipoprotein; GXM - glucuronoxylomannan 
2.4.4. Negative regulation of TLR signalling 
Uncontrolled inflammation responses are also dangerous and sometimes lethal as seen in 
autoimmune diseases and septic shock. TLRs together with PRRs are the first line of defence, they 
recognize danger signals and activate innate and adaptive immune system. It is, therefore, of primary 
importance to strictly control this response. Several mechanisms exist to control TLR-signalling. These 
regulatory mechanisms may act by restricting TLR activation or by inhibiting the ongoing TLR-
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signalling. TLR-signalling regulatory mechanisms can be categorized into three major groups: 
dissociation of adaptor complexes; degradation of signal proteins; and transcriptional regulation 
(180). So far several TLR signaling negative regulating molecules have been discovered. However, only 
a few will be exemplified in this thesis section. 
As for dissociation of adaptor complexes, several molecules are known to exist. TRAM adaptor 
with GOLD domain (TAG) and sterile alpha- and armadillo-motif-containing protein (SARM) are known 
to bind directly to TRIF, preventing this way the TRIF accessory molecules to bind and activate the 
TLR4 TRIF-dependent pathway (181,182). As for MyD88 dependent pathway interferon regulatory 
transcription factor 4 (IRF4), which is induced by TLR activation, is known to compete with IRF5 for 
MyD88 TIR domain binding, and, therefore, altering the IRF5-dependent gene induction (183). 
At the TLR-transcriptional regulation level, different classes of molecules are known to exist. 
Cyclic AMP-dependent transcription factor (ATF3), TLR-inducible inhibitor of kappa B (IκB) protein, 
nuclear receptor related 1 protein (Nurr1) are some of the known transcriptional TLR regulators. 
However, miRNAs have now emerged as fine tuners of TLR signaling by targeting TLR-mRNA and have 
been the subject of many studies in innate immunity relevant diseases and also in OA. 
MicroRNA miR-155 is a TLR-inducible miRNA with both positive and negative regulatory 
effects on immune responses (184-187). On one hand, TLR signaling is suppressed by miR-155 through 
targeting of MyD88, TGF-beta Activated Kinase 1 (TAB2) and IkB kinase (IKK) (184). On the other hand, 
miR-155 leads to increased TLR-signalling e.g. by targeting the anti-inflammatory lipid phosphatase 
SHIP (186,187). Together this suggests that miR-155 can fine tune TLR signalling depending on the cells 
and tissue TLRs are expressed.     
MicroRNA miR-146a was initially identified as a TLR4-induced miRNA that can target the 
signalling proteins TRAF6 and IRAK1 (188). Moreover, miR-146a upregulation leads to repression of 
IRAK1 expression levels which seem beneficial for healing of bacteria-induced tissue damage (189). 
Interestingly in cartilage retrieved from TKA patients, miR-146a expression appears to be upregulated 
in cartilage with low degradation further decreasing while cartilage degradation score increases (190). 
As it is also known receptor decoys are a general natural strategy to regulate the action of 
proinflammatory cytokines and chemokines (191). Interestingly, naturally present receptor decoy 
strategy for TLR-signalling receptor regulation has been also reported. Initially decoy receptor of TLR2 
was found in the bacteria-rich saliva. By then researchers were able to detect soluble TLR2 in human 
plasma and breast milk. Moreover, they were able to demonstrate monocyte production of sTLR2 and 
its negative regulatory properties of TLR2-mediated signalling. Interestingly sTLR2 presence in breast 
milk was speculated to have a role in avoiding an excessive local inflammation of the neonatal gut 
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following bacterial colonization (192).  Such ground-breaking work led to a biomimetic strategy of the 
construction of a recombinant soluble form of TLR4. This led to the demonstration in vitro that soluble 
TLR4 together with accessory molecule MD-2 is able to bind to LPS outside cell surface and attenuated 
LPS-mediated production of IL-8 (193). This was followed by in vivo proof of concept study which 
demonstrated the ability of recombinant sTLR4 together with sMD2 to damp LPS-induced pulmonary 
inflammation in mice (194). sTLR4 has then been found in several body fluids and species such as, in 
urine during acute renal failure in a mouse model, in human bacteria-rich saliva in oral lichen planus 
(OLP) saliva, and in human plasma of patients with inflammatory and autoimmune conditions (195-
197). Interestingly, sTLR2 present in breast milk was shown to mediate HIV infection and inflammation 
(198). Other body fluids reported to contain sTLR2 were saliva from oral lichen planus disease, parotid 
saliva, and human plasma of several inflammatory conditions (197,199,200). Given the role of innate 
immunity and TLR-mediated signalling in OA pathogenesis, it remains, therefore, to be seen if TLR 
decoy receptors are present e.g. synovial fluid from joint pathology conditions such as OA or RA. 
2.4.5.  TLR and their role in OA 
2.4.5.1. Synovium 
OA is a disease affecting the entire joint. Although the main feature of OA is cartilage degeneration, 
synovium and subchondral bone are also affected.  Synovitis is present in about half of the patients 
with OA and has been shown to correlate with cartilage damage severity (201). Therefore, TLR 
expression in the synovium is of interest. TLR 1-7 and TLR9 have been shown to be present in the 
synovium of OA patients, although not to the same extent as in those with RA (202,203). Moreover, 
functional studies in isolated primary FLS from normal, OA and RA patients have shown that expressed 
TLRs do actively respond to several DAMP ligands, such as tenascin-C or S100A8/A9 (104,204). TLR 
activation and the ensuing NF-kB activation followed by production of chemokines (e.g. IL-8 and CCL5) 
and cytokines (e.g. IL-1, IL-6 and TNF) are able to recruit macrophages, granulocytes and lymphocytes 
which indeed have been shown in the synovium of OA patients (152). Moreover, such secreted 
cytokines and chemokine can also cross talk with resident chondrocytes.  
Several DAMPs are present at increased concentration levels in the synovial joint fluid and 
tissues in the setting of joint injury and OA. The majority of them are cartilage degradation products, 
albeit some arise from cell apoptosis e.g. high mobility group box protein 1 (HMGB1). These include 
danger signals such as S100/calgranulin family (e.g., S100A4, the S100A8/A9 heterodimer, S100A11, 
S100A12), tenascin-C (TN-C), high and low molecular weight hyaluronan, fibronectin isoforms, and 
SLRPS such as biglycan and decorin (104,204-212). In this context, the observation that large majority 
of this DAMPs are TLR4 ligands, and TLR4 itself is a highly expressed TLR in synovial fibroblasts is of 
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interest (203). Moreover in TLR4 KO mice, synovitis is less pronounced as compared with wild-type 
mice when IL-1B is administered, indicating that perhaps local IL-1-driven joint pathology is dependent 
on TLR4 activation and the agonist expression (213). Interestingly, transient plasma proteins in SF were 
reported to induce TLR4-mediated inflammatory responses in macrophages, which as mentioned 
earlier infiltrate the OA synovium (152,214). 
2.4.5.2. Subchondral bone 
Subchondral bone alterations are known to occur in OA and events such as the development of 
osteoporotic and sclerotic bone under the cartilage degradation zones are fine examples of this 
intimate correlation (215). Mechanical loading and cross-talk between cartilage and intimately 
connected subchondral bone enable that the chondrocytes secrete catabolic, inflammatory and 
anabolic factors diffused throug cartilage to influence the subchondral bone microenvironment and 
vice versa (68,216). It is, therefore, interesting to note that also TLR2 and TLR4 are expressed in 
osteoblasts. Moreover, osteoblasts have the same ability as macrophages to down-modulate cytokine 
secretion during chronic TLR4 challenge (217). TLR signalling alters not only inflammatory properties 
of osteoblasts but also their osteogenic potential. Studies have shown that by activating TLR2 while 
TLR4 is inhibited, leads to increasing levels of osteogenic markers. On the other hand, if TLR4 is 
strongly activated this will downregulate osteogenic markers (218). In vivo studies using TLR2 KO mice 
showed an increased bone loss which in contrast was not observed in TLR4 KO. However, careful 
interpretation is necessary given that the observed bone loss effect was dependent on mice strains 
used (219,220).  In addition, TLR4 activation was shown to inhibit mouse osteoblast differentiation 
albeit in the co-presence of bone morphogenetic protein 2 (BMP-2) (221,222). TLR4 also has effects 
on another important bone remodelling cell, the osteoclast by modulating their formation, survival 
and activity (223,224). These findings are of particular importance given the known implication of 
bone mineral density, albeit conflicting reports, as a risk factor for OA development. There seems to 
be a lack of studies reporting TLR expression in human OA subchondral bone tissue. However, the 
known baseline expression of TLRs in human osteoblasts and osteoclasts, together with the known 
increased upregulation of TLR4 expression in subchondral bone in surgically induced OA mouse model, 
makes TLR-mediated inflammation of subchondral bone an important component of OA pathogenesis 
(225). 
2.4.5.3. Articular Cartilage 
As cartilage degradation is a central feature of OA, the joint innate immunity regulation by local 
chondrocytes is, therefore, of particular interest. Despite the generalized consensus of TLR expression 
in the synovial membrane, the same cannot be said of this finding in articular cartilage. Most probably 
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this is due to the fact that up until recently only a few consider this tissue as a primary mediator of 
inflammation in OA. Conflicting TLR expression profiles in chondrocytes and OA cartilage have been 
reported, particularly for TLR1 and TLR9, with only concordant results for TLR2 (156,157,226). 
Currently, OA progression is graded according to the degradation severity of OA cartilage. 
However, less is known about OA pathogenetic mechanisms and its key players such as TLRs during 
the disease progression. Interestingly, so far only one study has in fact shown that TLR4 seems to 
increase as the Mankin- histological score severity is increased during OA progression (227). 
Nevertheless, more studies would be beneficial to the field, by applying the same strategy to the other 
TLRs expressed in chondrocytes and their ligands, using updated and more consensual histological 
score such as the OARSI score (87).  
Cartilage matrix-mediated mechanotransduction mechanism and contribution to OA 
development has been gaining further support and evidence as one of the limitation factors of OA 
pathogenesis. It is interesting to note that TLR4 expression seems to be regulated by the applied shear 
stress to chondrocytes during time, with high shear stress causing TLR4 upregulation. In contrast, 
during prolonged shear stress TLR4 is downregulated. The ensuing inflammatory response and IL-6 
production was dependent on TLR4 upregulation (228). 
Several DAMPs such as low molecular weight hyaluronan, s100A8/9, fibronectin fragments 
and others, all with cartilage matrix origins have been shown to be recognized by TLRs expressed in 
chondrocytes. 
In line with cartilage ageing contribution to OA pathogenesis, advanced glycation end product 
(AGE) which are part of the existing DAMPs family, seem to accumulate at a higher rate in articular 
cartilage than in skin during natural aging. This increased presence of AGE was shown to accumulate 
particularly in the collagen network which in turn undermined its mechanical properties (229). Such 
increase of accumulation has been shown to be recognized by PRRs such as the receptor for advanced 
glycation end-products (RAGE) and TLR4 expressed in human chondrocytes leading to the response of 
secretion of catabolic factors such as IL-6, COX-2, HMGB1 and MMP-13. Interestingly AGE was not only 
recognized by TLR but also upregulated TLR4 expression levels (230). Together this suggests PRRs, and, 
in particular, TLR4 to be involved in age-related OA. 
Present in cartilage matrix, fibronectin is a glycoprotein which has been shown to be 
upregulated in synovial fluid and cartilage of OA patients (231,232). Initially, it was also shown that 
some fibronectin domains induce catabolic responses on cartilage (233). Later, it was shown that 
upregulated proteases participating in cartilage degradation of OA were able to cleave fibronectin into 
different fragments lengths similar to those found in OA cartilage (234). 
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It took the discovery of human TLRs to decipher further how fibronectin fragments were being 
recognized. While some fibronectin fragments have been shown to elicit catabolic responses through 
TLR2 recognition, the domain 13-14 of 29 kDA fibronectin fragment are also recognized by TLR4 
(226,235). 
Serum amyloid A, a TLR4 ligand, is also found at increased concentrations as OA severity 
increases. Serum amyloid A was found to be upregulated in the serum and synovium of OA patients 
and serum amyloid A levels correlated with radiographic progression of OA. In vitro studies further 
demonstrated serum amyloid A recognition by TLR4 in human chondrocytes and synovial fibroblast 
which resulted in increased production of cytokines and collagenases (236). 
Other known TLR ligands present at increased levels in the OA synovial joints are a member 
of the calcium-binding proteins family, specifically, S100A8 and S100A9. Initially, S100A8 and S100A9 
were found to be increased at cartilage lesions of RA patients. However, following studies from the 
same lab demonstrated that this particular feature was also true in OA cartilage lesions. S100A8 and 
S100A9 levels were correlated with expression of MMPs and proteoglycan depletion (237,238). 
Interestingly the initial studies demonstrated that chondrocytes were able to synthesize S100A8 and 
S100A9, and their synthesis was upregulated by known OA inflammatory factors such as IL-1β, TNFα, 
IL-17, and IFN (237). Further studies demonstrated that S100A8 and S100A9 were able to be 
recognized by TLR4 expressing chondrocytes, which induced catabolic responses leading to 
upregulated secretion of collagenases and aggrecanases while collagen type II and aggrecan were 
inhibited (238). The findings of this study were replicated in OA mouse models, where S100A8 and 
S100A9 stimulations caused a similar increase of known OA catabolic factors (239). Interestingly, 
S100A9 KO in experimental arthritis mouse model caused a decrease in osteophyte formation 
compared to the wild type. Moreover, S100A8 stimulation during murine mesenchymal stem cells 
(MSC) chondrogenesis leads to upregulation of collagenases, which indicate that local MSC actively 
participating in osteophytosis may be primed with the s100A8 ligand to continue osteophyte 
formation (240). Finally, S100A8 and S100A9 concentration levels at baseline of early symptomatic OA 
patients predicted osteophyte formation after 2 or 5 years (240). 
Besides the above-mentioned proteins, two other proteins with TLR activation properties and 
present in cartilage matrix have yet to be studied in OA regarding their inflammatory potential. 
Biglycan (BGN) and decorin (DCN) are two small structural proteoglycans with leucine-rich repeats 
(small leucine-rich proteoglycan, SLRP) composing cartilage matrix structure (89). However, if BGN or 
DCN are released from the cartilage matrix, possibly when the collagen network is disrupted and 
during tissue injury, their soluble forms could act as an endogenous danger signals (241). Several 
studies have shown that sBGN can trigger TLR2 and TLR4 activation in aortic valve cells, activate the 
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NLRP3 inflammasome, and to trigger acute ischemic kidney failure in mouse models (242-244). DCN, 
on the other hand, has been less studied. However, recent studies have shown it can activate TLR2 
and TLR4 leading to the production of proinflammatory mediators able to modulate and control 
tumour growth in a cancer mouse model (212). Several studies seemed to point to the direction of 
BGN and DCN having a role in OA, given their upregulation in OA cartilage and increased forms of BGN 
and presence of DCN auto-antibodies in SF from OA (245,246).  Table 4 resumes the known receptors 
expressed in the synovial joints and their know DAMPS and modulators present in OA joint. 
Table 4.  Known DAMPS and molecular modulators of TLRs present in the osteoarthritic joint. 
Receptor Receptor 
expression in OA 
synovial joint cell 
DAMP present in OA 
synovial joint 
Modulator of 
receptors in the 
synovial joint 
Reference 
TLR1/2 FLS, chondrocytes _______ _______ (202) 
TLR2 FLS, chondrocytes Fibronectin fragments, 
HMGB1 
Mechanical strain, 
TNF-α 
(247,248) 
TLR3 FLS, chondrocytes dsRNA _______ 147 
(202,249) 
TLR4 FLS, chondrocytes Fibronectin fragments, 
S100A8-A9, TN-C, LMW-
HA, HMGB1 
Mechanical stress, 
TNF-α, SF plasma 
proteins 
(248) 
TLR5 FLS, chondrocytes, 
bone 
Functionally proofed but 
ligand unidentified  
TNF-α, IL-8 (250) 
TLR6/2 FLS, chondrocytes Versican _______ (251,252) 
TLR7 FLS, chondrocytes ssRNA  (202,249) 
TLR8 FLS, chondrocytes ssRNA  (202) 
TLR9 FLS, chondrocytes dsRNA  (202) 
ssRNA: single-stranded RNA; dsRNA: double-stranded RNA; FLS: Fibroblast-like synoviocytes; TN-C: tenascin c; 
SF: synovial fluid; LMH-HA: low-molecular-weight hyaluronan; HMGB1: high-mobility group box 1; TNF-α: 
tumour necrosis factor alpha; IL-6: interleukin 6; IL-8: Interleukin 8; S100A9: S100 calcium-binding protein A9 
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3. Aims of the study 
The principal aim of this study was to  further extend the knowledge of how TLRs are regulated in OA 
with a particular focus on the role of chondrocytes. 
In order to achieve the principal aim of this study, we focused on addressing the following specific 
issues: 
A. To study the regulation of TLRs during the differentiation of chondroprogenitors, and the 
response of mature chondrocytes to inflammatory mediators present in OA. 
B. To study the regulation of TLRs in articular cartilage during the OA development in defined 
disease severity stages. 
C. To compare the expression of TLRs in articular cartilage from different osteoarthritic joints. 
D. To study synovial fluid for the presence of never reported endogenous ligands able to trigger 
TLR activation and study their possible impact on inflammatory mechanisms of OA and 
cartilage degradation. 
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4. Material and Methods 
4.1. Patients and samples 
4.1.1. Ethical aspects 
All patient samples used in studies of this thesis were approved by the ethical committees of Helsinki 
University Central Hospital (I, II, III), ORTON Invalid Foundation (I, II, III), and Biobanco-IMM (III). 
4.1.2. Patients with hyaline cartilage collected (Studies I, II, and III); tissue samples collection 
Twelve samples (10 women, 2 men) from distal trapezium were obtained during partial or complete 
trapeziectomy and arthroplasty performed for thumb basal joint OA. Patients mean age was 58.2 
(range 43-80). All patients had no pain relief or functional improvement after treatment with non-
steroidal anti-inflammatory drugs and a thumb spica splint. Eaton-Glickel grading system was used to 
assess the severity of the CMC-I OA (253). Non-erosive OA of the CMC-I was confirmed in all patients, 
after examining radiological features (9,254). Complete or partially excision (trapeziectomy) of the 
arthritic trapezium bone was performed depending on the presence of OA in the scaphotrapezial joint. 
Eaton-Glickel grade I OA patients were not included since it is a contraindication for arthroplasty. For 
healthy controls, cartilage-subchondral bone samples were obtained from the non-affected CMC-III 
joint, resected from patients undergoing total wrist arthrodesis for post-traumatic OA of the wrist. 
CMC-III joint was included in the wrist fusion to enable plate fixation from the third metacarpal bone 
to the distal radius. Healthy controls CMC-III were obtained from two male patients, 45 and 53 years, 
respectively. 
Fifteen osteochondral cylinder samples (11 women, 4 men) were prepared from tibial 
plateaus obtained from total knee replacements due to knee OA. Patients mean age was 67.5 (range 
52-87). The tibial plateau was fixed to an in-house purpose designed sample holder and samples were 
extracted from different areas of the joint surface using a hollow 9 mm bore attached to a power drill. 
Samples were graded for disease severity using the OARSI grading system (87). 
All samples were fixed in neutral buffered 10% formalin for 2 weeks and decalcified in 10% 
Ethylenediaminetetraacetic acid (EDTA), pH 7.4, for 5 weeks at 4 °C (until the bone tissue was pliable) 
before dehydration in ethanol series, clearing in xylene and embedding in paraffin. Samples were cut 
using a Leica RM 255 microtome (Leica, Wetzlar, Germany) to 3 μm thick sections and placed in 
microscope slides. 
45 
 
4.1.3. Patients whose cartilage was used for explant and primary chondrocytes cell culture 
(Studies I and III) 
Hyaline cartilage was collected from OA patients undergoing to total knee arthroplasty (TKA) (N=12) 
at ORTON Hospital. Half of the patients were female with a mean age of 63.5 (range from 53-73). 
Primary chondrocytes were also isolated from femoral heads from 4 femoral neck fracture 
arthroplasty patients, with no clinical history of inflammation or any macroscopically visible 
chondropathy. Tibial plateau containing cartilage and subchondral bone was cut off to provide space 
for the tibial component of the TKA implant. Samples were collected into sterile sample containers 
containing cold phosphate-buffered saline solution (PBS) and processed within four hours. 
4.1.4. Patients with synovial fluid collected (Study III) 
Samples with blood contamination were excluded. SF maintained at +4 °C was within two hours 
aliquoted into sterile Eppendorf tubes, snap frozen in liquid nitrogen and stored at −80 °C. After first 
thawing, SF was incubated with protease inhibitor cocktail (Roche Diagnostics, Meylan, France) and 
centrifuged at 1200 x g for 5 min at room temperature in order to separate solid debris and cells from 
the fluid phase. 
4.2. RNA extraction and cDNA synthesis (Studies II and III) 
Total RNA was isolated from cartilage explants by using the RNAqueous®kit (Thermo Fisher Scientific, 
MA USA) and from primary chondrocytes by using the RNeasy® mini kit (Qiagen, CA, USA). For MSc 
pellets total RNA isolation was done using TRIzol reagent (Invitrogen) followed by mRNa isolation using 
magnetic Oligo(dT)25 polystyrene beads (Dynal, Oslo, Norway). Isolated RNA quantity, purity and 
integrity were controlled with spectrophotometric analysis using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific). Complementary DNA (cDNA) synthesis for an equal 
amount of total RNA from each sample was performed using SuperScript® First-Strand Synthesis 
System (Invitrogen, CA, USA) for study II or iScript cDNA Synthesis Kit (Bio-Rad Laboratories, CA, USA) 
for study III and IV all accordingly to the manufacturers protocol.  
4.3. RT-PCR (Studies II and III) 
Quantitative RT-PCR was run in a LightCycler PCR machine using LightCyclerFastStart DNA Master SYBR 
Green I kit (Roche, Mannheim, Germany), twice for all samples. Primers were designed with Primer3 
(SourceForge, CA, USA), the sequences were searched with the NCBI Entrez search system, and 
sequence similarity search was done using the NCBI Blast program. The mRNA copy numbers were 
determined from each sample in duplicates. 
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Relative quantification of the gene levels was performed by comparing the Ct values of the 
different genes, correcting for beta-actin (ACTB) or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and TBP content (∆Ct) and for non-stimulated conditions (∆∆Ct) and then expressed as fold 
of changes.  
4.4. Cell and Tissue culture 
4.4.1. Cartilage explant culture, primary chondrocytes isolation, MSC isolation, chondrogenic 
cultures and culture stimulations (Studies I and III) 
Hyaline cartilage was extracted from TKA OA patients for cartilage and primary chondrocyte isolation 
and culture. Hyaline cartilage macroscopic appearance of the visible pathological changes in different 
sampling areas was collected following the arthroscopic grading scale of Société Française 
d’Arthroscopie (SFA) during harvesting (255). For study design purposes, samples were extracted from 
only two different types of areas: areas with no macroscopically visible lesions grade 1 OA 
(representing early OA cartilage degradation stages) or areas with full-thickness osteochondral lesions 
as the grade 4 OA (256). Such collection strategy was designed for stratified analysis of hyaline 
cartilage cultures based on the degree of OA cartilage, very mild vs. severe. Using a 4-mm circular 
punch biopsy blade (Kai Medical, Oyana, Japan) cylindrical full-thickness cartilage explants were 
obtained from graded tibial plateau areas and, subsequently, cultured in Dulbecco’s modified Eagle’s 
medium (DMEM)/F-12 (Life Technologies, Carlsbad, USA) supplemented with 50-100 U/ml penicillin, 
50-100 U/ml streptomycin and 0.25-0.3 μg/ml amphotericin B (Thermo Fisher Scientific) and 10% fetal 
calf serum (FCS) in cell culture chamber incubator for 24 h prior to stimulations.  
For chondrocyte isolation hyaline cartilage tissue was also used. Since chondrocytes account 
to only 1-3% of the volume of the cartilage, it is necessary to use the whole cartilage in order to obtain 
enough cells. Such process implies that the isolated chondrocytes represent a heterogeneous 
population of OA chondrocytes, therefore not allowing a stratified cartilage zone analysis. Cartilage 
specimens were then minced into 5 mg pieces and washed in sterile phosphate-buffered saline (PBS) 
followed by a sequential digestion in 2.5 mg/ml pronase and 250 mg/ml collagenase-P (Roche, Basel, 
Switzerland), with a PBS wash in between, for 60 min and overnight, respectively, under slow agitation 
at +37°C. The obtained cell suspension was filtered through a 70 μm nylon cell strainer, centrifuged, 
washed twice in sterile PBS, and seeded at 1.5x105/cm2 in DMEM/F12 supplemented with 10% FCS, 
100 units/ml penicillin, 100 units/ml streptomycin and 0.25 μg/ml amphotericin B (Thermo Fisher 
Scientific). Cells were maintained in cell culture chamber incubator for 3-4 days prior to stimulations. 
All steps were performed in sterile conditions under a cell culture chamber incubator. For 
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cryopreservation, cells were suspended in FCS containing 10% (v/v) dimethyl sulfoxide (DMSO) and 
frozen in an isopropanol container for 24 hours at -80°C before storage in liquid nitrogen. 
 Primary MSC lines were established from healthy adult donors, who had given their 
informed consent and following a protocol approved by an institutional review board. Mononuclear 
cells were isolated from 10 ml bone marrow aspirate using a density gradient (Ficoll-Paque Plus, GE 
Healthcare, Uppsala, Sweden) and plated at 4x106/cm2 in low glucose DMEM (Gibco, Thermo Fisher 
Scientific) supplemented with 10% FCS (StemCell Technologies, Vancouver, Canada), 100 U/ml 
penicillin, and 100 µg/ml streptomycin (all from Euroclone, Siziano, Italy). Non-adherent cells were 
removed by washing after 72 hours. Culture medium was changed twice weekly, and the passage 0 
cells were harvested using TrypZean (Sigma) from subconfluent cultures, usually fourteen days after 
plating. The cells were re-plated at 1000/cm2 in complete culture medium and passaged when 
subconfluent, as in agreement with earlier methods (257). Multipotency of the established cell-lines 
was tested with standard osteogenic and adipogenic protocols. For chondrogenesis experiments, MSC 
from passages three and four were used. MSC cells were washed twice in basal chondrogenic MSC 
Medium (Lonza, Basel, Switzerland) using resuspension and centrifugation at 150 x g for 5 min. 
Washed cells were transferred to complete Chondrogenic Medium (Lonza, Basel, Switzerland; 
supplemented with 10 ng/ml of transforming growth factor beta 3 (TGF-β3), R&D Systems, MN, USA) 
divided into different tubes each containing 2.5 x 105 cells and centrifuged again at 150xg for 5 min. 
Formed non-adherent pellets were kept in polypropylene tubes in cell culture chamber incubator. The 
medium was replaced every 3 days. Differentiation in the pellets was studied at days 0, 7, 14 and 21. 
Cartilage explants, primary chondrocytes, and chondrogenic pellets were stimulated with 
different concentrations and combinations of probe molecules at relevant time points. Table 5 
summarizes the cells exposure to the different proteins stimulations and stimulation duration. 
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Table 5. Molecular concentrations and duration of stimulations used in this thesis. 
Molecules/stimulus Concentration Duration (hours) Company Study 
Biglycan (sBGN) 5 µg/ml 24, 48 Sigma III 
CLI-095 1 μM 24, 48 Invivogen III 
Decorin (sDCN) 8 µg/ml 24 R&D Systems III 
LPS 1 µg/ml 24, 48 Sigma III 
Pam 3CSK4 0.5 ng/ml 12 Invivogen I 
Polymyxin B (PL-B) 25 mg/ml 24, 48 Invivogen III 
Proteinase K 50 mg/ml 24, 48 Thermo 
Scientific 
III 
TLR2 antibody 20 µg/ml 24, 48 Santa Cruz III 
TLR4 antibody 20 µg/ml 24, 48 Santa Cruz III 
rhTNF-α 5 and 100 ng/ml 12 R&D Systems I 
4.4.2. TLR4 reporter assay (Study III) 
Human HEK-blue TLR4 reporter cells (Invivogen) were seeded at 2.5 × 104 cells per well in a 96-well 
plate according to the manufacturer’s instructions. Human HEK-blue TLR4 reporter cells are 
genetically-modified to contain a TLR4/NF-κB/secreted embryonic alkaline phosphatase (SEAP) 
reporter construct to monitor the activation of NF-κB induced by TLR4 stimulation. To validate 
specificity stimulations were performed with ultra-pure lipopolysaccharide (LPS) preparation 
(Invivogen) (Table 5). Cells were stimulated with different molecules and solutions listed in Table 5. 
The conditioned medium of human HEK-blue TLR4 reporter cells culture stimulations in study 
III, was assed to measure the level AP activity engaged by the SEAP protein, using the commercial 
assay QUANTI-Blue™ (Invivogen). Controls, blanks and samples were mixed QUANTI-Blue™ medium 
preheated to +37°C, were incubated in wells of 96-well microplates for 1 hour at +37°C. After 
incubation, absorbance was measured at 655 nm in triplicates readings using a microplate reader 
(FLUOstar Omega, BMG LABTECH, Ortenberg, Germany). Samples relative AP activity was calculated 
from OD of samples relative to OD of controls. 
4.5. Biochemical and protein assays 
4.5.1. Soluble collagen assay (Study III) 
From cell culture stimulations of study III, the conditioned medium was used for measurements of 
concentrations levels of soluble collagen using the commercial assay Sircol™(Biocolor Ltd, 
49 
 
Carrickfergus, UK). Soluble Col-II standards, blanks and samples were mixed with collagen-binding 
Sircol Dye Reagent® in a mechanical shaker for 30 min at room temperature. Next samples were 
centrifuged at 12,000 rpm for 10 min. Samples were then drained, and the remaining collagen-dye 
pellet was washed with a salt-wash reagent followed by centrifugation at 12,000 rpm for 10 min. Next 
the collagen-dye complex was dissociated using an alkali reagent vortexing-wash (Biocolor Ltd.). After 
samples absorbances were measured at 540 nm, using a plate reader (Chamaleon-Hidex, Turku, 
Finland). Samples collagen concentrations levels were retrieved from the standard curve equation. All 
steps were performed at room temperature. 
4.5.2. Glycosaminoglycan Assay (Study III) 
The conditioned medium of cell culture stimulations of study III, was assed for the concentrations 
levels of sulfated glycosaminoglycan (sGAG) using the commercial assay Blyscan™ (Biocolor Ltd, 
Carrickfergus, UK). sGAG standards, blanks and samples were mixed with sGAG-binding Blyscan Dye 
Reagent® in a mechanical shaker for 30 min at room temperature. Next samples were centrifuged at 
12,000 rpm for 10 min. Samples were then drained, and the remaining sGAG-dye pellet was washed 
with dissociation reagent (Biocolor Ltd.), followed by centrifugation at 12,000 rpm for 5 min. Next 
samples were transferred into 96 well microplate and absorbances measured at 595nm using a plate 
reader (Chamaleon-Hidex). Samples sGAG concentration levels were retrieved from the standard 
curve equation. All samples and standards were run in duplicates. All steps were performed at room 
temperature if not otherwise stated. 
4.5.3. Nitric oxide measurement (Study III) 
Cell culture and tissue culture medium from study III were assessed for the presence and 
quantification of Nitric Oxide species (NO). NO was measured using a commercial nitrate/nitrite 
colorimetric assay kit (Cayman Chemical, Ann Arbor, USA).  Initially, cell and tissue culture medium 
samples were diluted with assay buffer in order to assure NO concentrations levels were within the 
detection range of the assay kit. This was followed by an addition of nitrate reductase and its co-factor 
for an incubation period of one hour and two hours for cell and tissue culture medium, respectively, 
at room temperature. This incubation time is essential to assure complete nitrate conversion to nitrite. 
Subsequently, samples were incubated with Griess reagents for 10 min at room temperature, which 
will cause nitrite to convert into a deep-purple colour compound. The light absorbance of this azo 
chromophore accurately determines NO concentration. Absorbance was measured at 544 nm using a 
plate reader (Chameleon-Hidex). NO concentration levels were calculated from standard curve 
equation. All samples and standards were run in duplicates. 
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4.5.3.1. Safranin-O staining (I,II,III) 
Formalin-fixed paraffin-embedded (FFPE) tissue sections from OA cartilage were stained with 
Safranin-O for evaluation of cartilage proteoglycan (PG) content. Sections were deparaffinised in 
xylene and rehydrated in ethanol series using an automated immunohistochemical robot (Varistain 
XY, Shandon, Thermo Scientific). This was followed by a rinsing during 10 min in Weigert’s Iron 
Hematoxylin working solution (Merck, Darmstadt, Germany), followed by a wash in H2O for 10min 
with a 15 seconds rinsing intermediate step in a differentiation solution (1% HCl in 70% alcohol ). This 
was followed by a 5 min rinsing in a Fast Green solution (SIGMA, C.I 42053, MO, USA), and a rinse in 
1% Acetic Acid solution for 15 seconds. The sections were then rinsed for 5 min in 0.1% Safranin-O 
solution (Fluka-SIGMA). Sections were then manual dehydrated in a series of ethanol, cleared in xylene 
and mounted. All steps were performed at room temperature if not otherwise stated. 
4.5.3.2. Alcian blue staining (Study II) 
OA cartilage FFPE sections were stained with Alcian blue for evaluation of cartilage proteoglycan 
content and as an alternative comparison with Safranin-O staining. Sections were deparaffinised in 
xylene and rehydrated in ethanol series using an automated immunohistochemical robot (Varistain 
XY). This was followed by a rinsing during 30 min in Alcian blue solution (Sigma), followed by a wash 
in H2O for 2 min. This was followed by a 5 min rinsing in a nuclear fast red solution (Sigma), and a rinse 
in H2O for 1 min. Sections were then manual dehydrated in a series of ethanol, cleared in xylene and 
mounted. All steps were performed at room temperature if not otherwise stated. 
4.5.4. Protein expression  
4.5.5. Immunohistochemistry (Studies I, II, and III) 
Cartilage samples and MSC pellets paraffin sections were used for immunohistochemistry (IHC) 
studies. Sections were deparaffinised in xylene and rehydrated in ethanol series using an automated 
immunohistochemical robot (Varistain XY). This was followed by antigen retrieval in 10 mM citrate 
buffer, pH 6.0, for 1 hour at 70°C and 10 mM sodium citrate buffer, pH 6, followed by AR 98ºC-S30M 
program for 24 min in MicroMed T/T Mega Laboratory Microwave Systems (Milestone, Sorisole, Italy), 
for cartilage and MSC pellets respectively. After quenching of endogenous peroxidase in 0.3% H2O2 in 
deionized water for 25 min, sections were blocked with normal goat serum or normal horse serum 
(Vectorlabs, CA, USA) diluted in 0.1% bovine serum albumin-phosphate buffered saline (BSA-PBS) for 
1 h. Sample sections were then incubated overnight at 4°C with TLRs, CD31, CD34, CD105, CD166, 
COL2A-3/4M and TNF-α at specific concentrations (Table 6). This was followed by a 1h incubation 
period in biotinylated goat anti-rabbit or horse anti-mouse IgG (Vectorlabs). Next avidin-biotin-
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peroxidase complex were developed during 1h followed by the addition of colour developer solution 
H2O2-3,3’-diaminobenzidine (DAKO A/S, Glostrup, Denmark) during 10 min, succeed by washing step 
in distilled water and counterstaining in Mayer hematoxylin (Merck, Darmstadt, Germany) for 1 min. 
After that the slides were dehydrated in ethanol series, cleared in xylene and mounted.  For negative 
staining controls non-immune IgG was used instead of and at the same concentration as the primary 
specific antibodies. All incubations were performed at 22°C in humidified chambers, with 3 times PBS 
washes in between the steps if not otherwise stated. 
Table 6. Concentrations of primary antibodies used for IHC in the studies. (*) primary antibody 
concentration used for MSC pellets immunostainings 
Antibody Type Dilution Manufacturer Study 
TLR1 Polyclonal rabbit IgG 2/0.8* μg/mL Santa Cruz Study I, II 
TLR2 Polyclonal rabbit IgG 1/2.6* μg/mL Santa Cruz Study I, II 
TLR3 Polyclonal rabbit IgG 2 μg/mL Santa Cruz Study I 
TLR4 Polyclonal rabbit IgG 1.3-1 μg/mL Santa Cruz Study I, II 
TLR5 Polyclonal rabbit IgG 1.3 μg/mL Santa Cruz Study I 
TLR6 Polyclonal rabbit IgG 1 μg/mL Santa Cruz Study I 
TLR7 Polyclonal rabbit IgG 0.8 μg/mL Santa Cruz Study I 
TLR8 Polyclonal rabbit IgG 1 μg/mL Santa Cruz Study I 
TLR9 Polyclonal rabbit IgG 1/2.5* μg/mL Santa Cruz Study I, II 
TLR10 Polyclonal rabbit IgG 1.6 μg/mL Santa Cruz Study I 
CD31 Polyclonal rabbit IgG 18 μg/mL Santa Cruz Study II 
CD34 Polyclonal rabbit IgG 2 μg/mL Santa Cruz Study II 
CD105 Monoclonal mouse IgG2a 10 μg/mL Abcam Study II 
CD166 Polyclonal rabbit IgG 1 μg/mL Abcam Study II 
Collagen II Mouse IgG1 6.65 μg/mL Chemicon Study II 
COL2A-3/4M Polyclonal rabbit IgG 1:1000 μg/mL Ibex Study I, II 
TNF-α Mouse IgG 10 μg/mL 
Research 
Diagnostics Inc. 
Study I 
4.5.6. Enzyme-linked Immunosorbent Assay (ELISA) (Study III) 
Stored synovial fluid samples were thawed until they were at room temperature. SF samples were 
used to measure the concentration levels of intact- only sBGN and sDCN using specific sandwich 
Enzyme-linked Immunosorbent Assay (ELISA) (all purchased from Uscn Life Science Inc., Hubei, PRC). 
52 
 
Initially, SF samples were diluted to the optimum working range after initial pilot runs were performed. 
Samples were incubated in 96 well strip plates coated with the respective antibody. Next samples 
were washed and incubated with avidin conjugated to horse radish peroxidase (HRP) followed by a 
second wash step and incubation in biotin. Colour was then developed by an incubation period in 
substrate solution. Absorbance was measured at 450 nm using a plate reader (Chameleon-Hidex). SF 
samples concentrations of sBGN and sDCN were determined by comparing the OD of the samples to 
the standard curves were exact concentrations of the respective recombinant proteins were used. All 
samples and standards were run in duplicates. All incubation periods were performed at 37 ⁰C. 
4.5.7. Luminex xMAP® technology (Study III) 
Protein concentration levels secretion into cell culture supernatant was done using xMAP® technology 
(Luminex, TX, USA). A custom detection multiplex kit was designed to detect the following targets: 
MMP-1, MMP-3, MMP-9 and MMP-13, IL-6, and IL-8. The detection-multiplex kit (ProcartaPlex-
eBioscience, CA, USA) was run in combination with xMAP® technology on the Bio-Plex 200® system 
(Bio-Rad Laboratories, Hercules, CA, USA). Cell culture supernatant was diluted (diluted 1:2) before 25 
µl of supernatant per sample was used for the assay.  
4.6. Grading of OA patients and OA samples 
4.6.1. Radiographic grading of CMC-I OA using the Eaton-Glickel grading system (unpublished 
data) 
The radiological Eaton-Glickel scale was used to evaluate the disease severity of the CMC-I OA (253). 
It would have been preferable to use a histological grading as OARSI grading. However trapeziectomy 
was sometimes only partial which lead to non-uniform sampling zones. Sampling uniformity is an 
essential feature for OARSI grading. Still, radiological grading of hand OA correlates positively with the 
histological assessment in post-mortem samples (258). Therefore, both scales reflect the severity 
(grade) of OA. 
4.6.2. Histopathological grading of osteoarthritic cartilage (Study I and II) 
The histopathological OARSI grading was carried out blindly by 3 independent researchers from coded 
samples using light microscopy. Researchers were familiar with OARSI grading methodology and used 
OARSI templates as guidance (87). Associated features to OARSI grade of OA cartilage can be seen in 
Table 2. 
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Stained samples were evaluated under a Nikon LV-DIA-BASE microscope (Nikon, Tokyo, Japan) 
provided with a motorized XY-stage (Scan Prior III, Prior, Rockland, MA, USA), connected to a DS-Fi1 
digital camera using Nikon Imaging Software (NIS) - Element Basic Research (BR) analysis (Nikon). 
4.7. Image analysis 
4.7.1. Histomorphometry (Study II and in unpublished data) 
The TLR-positive cells percentage was calculated from at least 5 high-magnification (200×) fields 
separately for the surface, middle, and deep zones of the hyaline articular cartilage.  
4.8. Statistical analysis (Study I, II, and III) 
Student's t-test was used for comparison of paired samples. The non-parametric methods One-way 
ANOVA, Mann-Whitney and Wilcoxon sign-rank test were used for multiple group comparisons, as 
appropriate. Relevant post-hoc tests were performed for all statistical hypothesis tests.  Effects of 
covariates were analysed by multiple linear regression. All statistical analysis were performed using 
SPSS v. 21 (IBM Corp, NY, USA). Data is presented as mean and standard deviation (SD). P-values < 
0.05 were considered significant.  
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5. Results 
5.1. TLR1, 2 and 9 expression in healthy articular chondrocytes (Study I) 
Given the conflicting reports on the expression of TLR1, 2 and 9 in human articular chondrocytes we 
decided to study the expression of these TLRs in in chondrocytes to settle the apparent literature 
discrepancies. Moreover, as these TLRs recognize several DAMPS, which could arise from cartilage 
ECM breakdown and biological processes, and they contribute to the pathogenic mechanism in the 
osteoarthritic synovial joint it would be of utmost importance to elucidate their expression in synovial 
joints.  
TLR1, TLR2 and TLR9  mRNA expression  was studied in isolated chondrocytes obtained from 
trauma patients with no clinical history of inflammation or any macroscopically visible chondropathy. 
Primary chondrocytes were expanded in monolayer cultures (2D culture) during one passage to obtain 
sufficient amounts of isolated RNA. As the results in Figure 5 disclose, TLR1, TLR2 and TLR9 were 
detected in healthy primary chondrocytes, albeit at different relative mRNA expression levels.  
 
Figure 5. Toll-like receptors TLR1, TLR2, and TLR9, are expressed in primary chondrocytes. TLR1 and TLR2 mRNA 
levels were higher than TLR9 mRNA levels relative to a housekeeping gene († p < 0.001).  Cells were isolated 
from four different donors (N=4).  
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5.2. TLR1, 2 and 9 expression during mesenchymal stem cells chondrogenesis 
During traumatic events, cartilage matrix products are released and they can initiate a danger signal 
driven inflammation response by local resident cells. By using MSCs which are directed towards 
chondrocyte differentiation we believed we could study a human mature chondrocytes in micro-
environment free of danger signals or inflammatory mediators and their products which can 
potentially alter TLR expression levels. Moreover, MSCs are widely being studied to be used as for 
cartilage repair and also for blocking ongoing inflammation given their anti-inflammatory properties. 
Studying TLR1, 2 and 9 expression during chondrogenesis and comparing differentiated mature 
chondrocytes (21 days) with phenotypically healthy chondrocytes seemed, therefore, a necessary 
analysis.  
As demonstrated in Figure 6 and Figure 11 collagen type II and Safranin-O PG staining confirm 
the differentiation of MSC into mature chondrocyte cells (21 days). Collagen type II and PG are 
essential components of cartilage matrix and the main molecules compromised during osteoarthritic 
cartilage degradation and chondrocyte phenotypic changes. Furthermore SOX9 and COL2A1 gene 
expression levels, two gene markers of articular chondrocyte, were upregulated by 9 (±7) and 570 
(±92) folds respectively, when compared to the negative control undifferentiated MSCs kept for 21 
days in regular medium. 
As for TLR1, 2 and 9 expression during chondrogenesis their mRNA expression was reduced 
significantly from the progenitor stage until the mature differentiated chondrocytes, as Figure 7 
shows. However, TLR1, 2 and 9 expression levels did not follow exactly the same expression patterns 
during the conventional differentiation stages. TLR1 and TLR2 proteins were also detected by 
immunostaining, as Figure 8 shows. 
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Figure 6. Toll-like receptors immunostainings of chondrocyte pellets at day 21 produced from human bone 
marrow-derived mesenchymal stem cells. A-C. TLR1, TLR2 and TLR9 immunostaining, respectively, D, compared 
to a negative staining control. Original magnification 200x. Insets, lower magnification general view of the 
chondrogenic pellets. Original magnification 100x. 
 
Figure 7. Toll-like receptors expression during chondrogenesis of human bone marrow-derived mesenchymal 
stem cells. Toll-like receptors TLR1, TLR2 and TLR9 in mesenchymal stem cells (day 0) differentiating via 
progenitor stage (day 7 and 14) to chondrocytes (day 21). Quantitative real time-polymerase chain reaction was 
used to measure the mRNA copy numbers per 106 β-actin copies. In primary chondrocyte isolates TLR1 and TLR2 
mRNA relative expression was higher than TLR9 (*p<0.05). Overall gene expression changes of TLR2 and TLR9 
were statistically significant during chondrogenesis period. Each dot represents one sample. Shown are mean 
values (± the standard deviation [SD]) from 4 independent experiments (using samples obtained from 4 different 
biological donors). Samples were measured as technical duplicates and averaged. 
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Figure 8. Chondrocyte pellets at day 21 produced from human bone marrow-derived mesenchymal stem cells. 
A, Collagen type II immunostaining. B, negative control. Original magnification 200x. Insets, Lower magnification 
general view of the chondrocytes pellets at day 21. Original magnification 50x. 
5.3. Chondrocyte TLR1-TLR2 heterodimer activation 
After TLR1 and TLR2 expression was confirmed by gene expression analysis, we then tested their 
functionality. We used Pam3CSK4 a known synthetic triacylated lipopeptide (LP) that mimics the 
acylated amino terminus of bacterial LPS. Pam3CSK4 activates innate immunity through the NF-κB 
pathway and is recognized by the TLR1-TLR2 heterodimer.  
Both primary chondrocytes from trauma patients and MSC-derived chondrocytes cultured for 
21 days were stimulated with Pam3CSK4. As one of the measurements of innate immune 
inflammatory activation we decided to measure the TNF-α gene expression, given it's known 
proinflammatory properties and increased levels in OA synovial joints and tissues. Pam3CSK4 caused 
upregulation of TNF-α mRNA expression levels in both chondrocyte cell types, however this was only 
statistically significant in MSC-derived chondrocytes cultured for 21 days (Figure 9). Interestingly TLR1 
and TLR2 mRNA expression levels were also upregulated in both chondrocyte cell types upon addition 
of Pam3CSK4 demonstrating TLR1-TLR2 heterodimer activation. In contrast, as expected TLR9 
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expression levels remained unchanged (Figure 9). Together the results also show that MSC-derived 
chondrocytes cultured for 21 days are able to regulate TLR and TNF-α mRNA expression with a similar 
pattern as observed in primary chondrocytes. 
 
Figure 9. Pam 3CSK4 stimulation of primary chondrocytes and MSC-derived chondrocytes cultured for 21 days. 
(A) In primary chondrocytes stimulated with Pam 3CSK4, TLR1, TLR2 and TNF-α mRNA levels are significantly 
upregulated. (B) In MSC-derived chondrocytes stimulated with a Toll-like receptor 1/2 specific ligand Pam 3CSK4, 
lead to a significantly upregulation of Toll-like receptors TLR2 and TLR9. Mean ± standard deviation, compared 
to unstimulated cultures. *p<0.05 
5.4. TNF-α stimulation of chondrocytes  
As shown in the previous results, a ligand such as Pam3CSK4 which is recognized by the TLR1-TLR2 
heterodimer can cause the upregulation of TNF-α. However, TNF-α can also arise from other innate 
immune inflammatory pathways involved in OA pathogenesis, such as the complement system. It is, 
therefore, important to know how this inflammatory cytokine influences TLR expression and 
activation.   
As shown in Figure 10, recombinant human TNF-α at 5 ng/ml and the supraphysiological 
concentration of 100 ng/ml caused the upregulation of TLR1 and TLR2, in a dose-dependent manner. 
Interestingly, TLR9 expression remained fairly unchanged in both TNF-α concentrations. TNF-α 
stimulations also caused an increase in TNF-α mRNA expression levels in MSC-derived chondrocytes 
cultured for 21 days at both TNF-α concentration levels.  
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Figure 10. TNF-alpha stimulation of MSC-derived chondrocytes cultured for 21 days. Folds of changes of tumour 
necrosis factor-α (TNF-α), Toll-like receptor 1 (TLR1), TLR2 and TLR9 upon stimulation of MSC-derived 
chondrocytes with 5 and 100 ng/ml rhTNF-α. Mean ± standard deviation, compared to unstimulated cultures. 
*p<0.05 
Stimulation of 21 day MSC chondrocyte pellets with TNF-α at 0, 5 and 100 ng/ml also caused 
a dose-dependent loss of GAG deposited in the formed ECM matrix surrounding the mature 
chondrocytes (Figure 11). Safranin-O staining is a cationic-based dye which can stain the negatively 
charged GAGs. Depletion of GAGs implies that TNF-α stimulation lead to activation of aggrecanases 
which can cleave the aggrecans supramolecular structure as well of the core proteins of aggrecan 
attached GAGs. 
60 
 
Figure 11. Safranin- O staining of MSC-derived chondrocytes cultured for 21 days. A, untreated (control), B, C, 
treated with 5 and 100 ng/ml of TNF-α, respectively. Safranin-O staining is markedly decreased from pellet 
borders towards the pellet centrum. Original magnification 50x. 
Since the loss of GAGs is associated with disruption of collagen network structure, we then 
studied wether the main cartilage collagen type, collagen type II, was damaged. Staining of 21 days 
MSC chondrocyte pellets with COL2A-3/4M neoepitope antibody (currently known as C2C) specific for 
collagen type II (cleavage by MMP-1, MMP-8 and MMP-13), demonstrated increased staining after 
TNF-α stimulations (Figure 12). Immunostaining of COL2A-3/4M was observed in chondrocytes and 
surrounding ECM matrix.  
Figure 12. Immunostaining with the COL2A-3/4M antibody of MSC-derived chondrocytes cultured for 21 days. 
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(A) unstimulated control and (B) negative staining control. (C) MSC-derived chondrocytes cultured for 21 days 
stimulated with 5 ng/mL TNF-α and (D) stimulated with 100 ng/mL TNF-α. Note the marked increase of COL2A-
3/4M immunostaining in TNF-α stimulations. Magnification 100×. 
5.5. TLR expression is dependent on the severity of OA (Study II and unpublished data) 
TLR have been shown to be present in chondrocytes obtained from knee and hip joints of healthy and 
OA patients. However, TLR expression during OA progression has not been studied, despite it could 
offer clues of their involvement in the disease development. Moreover, no study so far has addressed 
TLRs expression in other OA joints besides the knee joint. Therefore, we decided to study by IHC the 
expression patterns of all human TLRs in cartilage obtained from knee and CMC-I joints of OA patients 
accordingly to a well validated histological and radiographical scores of OA severity. For the CMC-I 
joint OA severity we used a validated OA radiographic score, due to the incompatibility of a histological 
score to the non-uniform sampling of cartilage from the CMC-I joint. 
As Figure 13 demonstrates, we were able to detect all human TLRs in cartilage from knee OA 
at the OARSI histological grade 2, with TLR positive chondrocytes already detected in the middle zone 
of knee articular cartilage. TLRs immunostainings were specifically localized to chondrocytes with very 
weak levels of ECM background stainings. 
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Figure 13. Immunostainings of Toll-like receptors (1 to 9) in knee OA cartilage with OARSI grade II. All TLRs 
stained positive in OA cartilage sample with OARSI grade II. TLRs positive stainings are observed in cartilage 
surface and middle zones. Negative staining control, rabbit IgG, confirmed the specificity of the 
immunostainings. Representative pictures of N=15 had similar results. Original magnification ×100. 
Interestingly, in contrast to TLRs staining pattern in knee OA, TLR immunostaining were 
substantially different in cartilage from CMC-I OA of grade II. Instead, we observed very 
heterogeneous TLRs immunostainings across samples of the same equivalent grade (Figure 14). CMC-
I joint samples were graded accordingly to the Eaton-Glickel grading system which is based on 
radiological observations. Figure exemplifies the Eaton-Glickel grading of patients whose samples 
were collected, with the exception of stage I samples which were not collected since trapeziectomy is 
a clinical contraindication. 
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Figure 14. Immunostainings of Toll-like receptors (1 to 9) in CMC-I OA cartilage with Eaton-Glickel grade 2. 
Immunostainings clearly indicates the expression of all TLR1, TLR2, TLR3 and TLR6 in the Eaton-Glickel stage 2 
patient sample. Negative staining control, rabbit IgG, confirmed the specificity of the stainings. Representative 
pictures of N=15 were similar results were observed. Original magnification ×100. The data is unpublished. 
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Figure 15. Eaton-Glickel radiological grading of OA lesions of the CMC-I joint. Grade I: Normal or only slightly 
widened joint space (due to joint effusion or synovitis). Grade II: Mild CMC-I cartilage space narrowing and small 
osteophytes or loose bodies < 2 mm in diameter. Grade III: Significant narrowing or complete obliteration of the 
CMC-I joint space with osteophytes or loose bodies > 2 mm in diameter. Grade IV: Same as grade III, but also 
the scaphotrapezotrapezoidal (STT) joint is affected. The data is unpublished. 
Histomorphometric analysis of immunostainings of TLRs in cartilage samples from knee OA 
across OARSI grades revealed a rather similar and homogeneous increase of the proportion of TLR+ 
chondrocytes as the OARSI score increased (Figure 16). 
Figure 16. Toll-like receptors expression in chondrocytes resident in knee OA cartilage zones and during OARSI 
grade progression. Knee OA cartilage degradation stages were graded according to the Osteoarthritis Research 
Society International (OARSI) histological score. Knee cartilage zones evaluated were the surface (gliding, 
tangential), middle (transient), and deep (vertical) zones. TLR10 was not found in any of the studied cartilage 
samples from knee OA. *p < 0.05, **p < 0.01 indicate statistical significant differences for pairwise comparisons 
of histomorphometric levels in cartilage zone differences of TLR expression in different OARSI grades (G), 
66 
 
separately for the surface zone (first asterisk) and for the middle zone (second asterisk). N=3 per each OARSI 
grade. 
In comparison, immunostainings of TLRs in CMC-I OA samples across Eaton-Glickel grade 
revealed a rather heterogeneous pattern of the proportion of TLR+ chondrocytes (Figure 17). As can 
be observed, there was a great variation within same grade further stressing that TLRs expression in 
cartilage from CMC-I OA is patient-dependent. Interestingly the only striking pattern was the 
homogenous relatively low or absent expression of TLR4 immunostaining across all studied samples. 
Figure 17. Toll-like receptors expression in chondrocytes resident in CMC-I OA cartilage zones and during SFA 
stage progression. CMC-I OA cartilage degradation stage were graded according to the French Arthroscopy 
Society (SFA) radiological score. CMC-I cartilage is particularly small hence no zone stratification analysis is 
possible. TLRs expression was heterogeneous with no statistical significance during stage progression. N=4 per 
each SFA score. This data has not been published. 
PCA was performed over histomorphometric data to assess the relationships of individual TLRs 
variables across all dataset. PCA identified no significant difference between TLR expression profiles 
from samples of knee OA. On the other hand, PCA revealed significant differences in CMC-I OA. PC1 
and PC2 disclosed two clusters separated by 95% confidence ellipsoids, one cluster being composed 
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of TLR1-3, TLR5 and TLR6 while the other of TLR7-9 (Figure 18). PC1 (56%) and PC2 (20.7%) 
represented 76.7% of the data. TLR4 did not belong to these two TLR clusters and correlated 
negatively to the higher expression of all the other TLRs.  
 
Figure 187. Principal component analysis (PCA) of the histomorphometric TLR data in OA cartilage of the CMC-I 
joint. Score plot of PCA with PC1 and PC2 component extraction in a rotated space. 95% Confidence ellipsoids 
drawn by PCA show a clear separation of the TLR7, TLR8 and TLR9 cluster from the TLR1, TLR2, TLR3 and TLR5 
cluster and that TLR4 has no association with either. The eigenvalue 1 criterion was used to select the PCs. 
Loading values vary from -1 to 1 and represent correlation of the variable with the principal components. Missing 
data cases were excluded list wise. Oblique promar and orthoganal varimax rotations produced similar results. 
This data has not been published. 
5.6. Identifying clinically relevant endogenous ligands able to activate TLR4 in OA joints (Study III) 
SLRPs are essential matrix components of articular cartilage. We hypothesized that class I SLPRs BGN 
and DCN, could be released from the matrix and become available in their known soluble 
proinflammatory forms. The detection and study of their biological role is of significant relevance to 
the knowledge of the pathomolecular mechanisms of OA. 
We, therefore, started by analysing synovial fluid, which is in direct contact with articular 
cartilage, for the presence of sBGN and sDCN using specific sandwich ELISA assays. The sBGN and sDCN 
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ELISAs were performed in SF from knee meniscectomy, OA and RA patients. Results clearly show 
higher sBGN levels in OA (582 ± 307 ng/ml) in comparison to meniscectomy patients (14 ± 2 ng/ml).  
SF from RA patients had the highest levels of soluble BGN, with levels up to 80 folds higher than those 
in meniscectomy patients. SF-sBGN concentration levels were significantly different between all 
groups (Figure 19 A). In sharp contrast to sGBN results, sDCN concentrations levels were up to 10 fold 
lower and remained constant across all arthritic groups (Figure 19 B).  Covariates (age, gender and 
body mass index) tested with multiple linear regression models showed no association with SF-sBGN 
and sDCN levels. 
 
Figure 19. Soluble biglycan and decorin concentrations levels measured by ELISA assay in synovial fluid from 
different arthritic conditions groups. A, sBGN concentration levels were significantly increased in knee SF from 
TKA OA and RA patients when compared to meniscectomy patients. B, sDCN concentration levels remain 
unchanged in knee SF from meniscectomy, TKA OA and RA patients. Each dot represents one sample. Shown are 
mean values (± the standard deviation [SD]) from ten independent samples. **p < 0.01, ****p < 0.001 indicate 
statistical significant differences between pairwise comparisons groups. Knee SF samples were obtained from 
10 patients (N=10) to each arthritic group. 
The fact that sBGN was increased in synovial fluid from OA patients was a strong indicator of 
its potential pathophysiological role. We then decided to study whether sBGN could influence the 
cartilage metabolism, due to its known proinflammatory role in other diseases. Given the knowledge 
about the role of markers of joint destruction in OA, we studied whether sBGN stimulation had any 
effect on their expression. In OA primary monolayer chondrocytes sBGN significantly increased gene 
expression of ADAMTS4, ADAMTS5, MMP13, CTSK and MMP9, almost as efficiently as LPS, which was 
used as positive control for TLR4 activation (Figure 20A). A similar response was observed in cartilage 
explant tissues obtained from patients with different severity of OA. However, the degree of response 
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to sBGN was dependent on the grade of cartilage degradation. The mRNA expression of markers of 
joint destruction were more upregulated in grade I OA cartilage in comparison to grade IV OA cartilage 
(Figure 20B). 
Figure 208. Effect of soluble biglycan (sBGN) on the gene expression of proteinases associated with matrix 
remodelling and cartilage degeneration in osteoarthritis. (A) In OA primary chondrocytes sBGN stimulation lead 
to upregulation of proteinases examined. Lipopolysaccharide (LPS), the positive control, caused a similar 
increase although at different scale reflecting it is known potent activation of TLR4. (B) In OA cartilage explants 
sBGN induced the upregulation of MMP9, MMP13, ADAMTS5 and CTSK in grade I OA, while in severe grade IV 
OA sBGN did not alter their expression levels. Results are expressed as fold changes (Mean and SD) relative to 
TATA Box Binding Protein (TBP) housekeeper and compared to non-stimulated controls. Samples were run as 
technical duplicates, and each experiment was done using samples obtained from at least 6 different donors 
(biological replicates). *p<0.05, **p<0.01, ***p<0.001 vs. non-stimulated controls or pairwise comparisons. 
ADAMTS = a disintegrin and metalloproteinase with thrombospondin type 1 motif; MMP = matrix 
metalloproteinase; CTSK = cathepsin K. 
The presence of joint destruction markers were also confirmed on the protein level by 
Luminex Xmap technology. Stimulation with sBGN caused increased release of the markers into cell 
culture supernatant of OA primary chondrocytes (Figure 21). In addition proinflammatory cytokines 
IL-6 and IL-8, both mediators of joint destruction, were also upregulated by sBGN stimulation. Due to 
the limited number of samples statistical analysis could not be applied. 
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Figure 21. Effect of soluble biglycan (sBGN) on the expression MMP-1, -3, -9 and -13 and IL-6 and IL-8 proteins 
in OA primary chondrocytes. (A-E) Cell culture supernatant concentration levels of MMP-1, -3, -9 and -13 and IL-
6 and IL-8 proteins, respectively. sBGN lead to the upregulation of several markers of joint destruction known 
to play a role in OA. sBGN-induced concentration levels compared to controls did not reach the statistical 
significance p-value <0.05. Results are expressed as ng/ml or pg/ml concentration levels. Each dot represents 
one sample. Shown are mean values from 3 independent experiments (using samples from 3 different biological 
donors). Samples we measured as technical duplicates and averaged. 
Altered cartilage turnover is a prominent feature of OA. Therefore we studied wether sBGN 
also had influence on the anabolic functions of OA chondrocytes. In primary OA chondrocytes sBGN 
significantly inhibited aggrecan and Col-II mRNA expression (Figure 22).  On cartilage explants the 
response was dependent on the OA grade of cartilage severity, with grade I OA explants able to keep 
maintaining the expression of Col-II much in contrast with down-regulation observed in explant from 
grade IV OA (Figure 22). 
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Figure 22. Effects of soluble biglycan (sBGN) on the expression of aggrecan (ACAN) and collagen type II (COL2A1). 
(A) In primary chondrocytes sBGN stimulation lead to down-regulation of ACAN and COL2A1. Lipopolysaccharide 
(LPS), the positive control, lead to a similar response. (B) In OA cartilage explants sBGN stimulation leads to a 
down-regulation of COL2A1 levels in grade I OA which was significantly different from the observed response in 
grade IV OA. ACAN levels were not altered significantly after sBGN stimulation. Results are expressed as fold 
changes (Mean and SD) relative to TATA Box Binding Protein (TBP) housekeeper and compared to non-
stimulated controls. Samples were run as technical duplicates, and each experiment was done using samples 
obtained from at least 6 different donors (biological replicates). *p<0.05, **p<0.01 vs. non-stimulated controls 
or pairwise comparisons. 
In situ cartilage explant degradation by sBGN-catabolic chondrocytes was confirmed by 
analysis of cell culture media for the release of PGs and soluble collagen. Release of sGAG was more 
notable in grade I OA explants, whereas sBGN-induced increased collagen release was observed in 
grade IV OA cartilage (Figure 23). 
Figure 239. Effects of soluble biglycan (sBGN) on the release of glycosaminoglycans and soluble collagen from 
cartilage explants compared to non-stimulated controls. (A) In grade I OA, the sBGN stimulation lead to an 
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increased release of glycosaminoglycans. (B) In grade IV OA, sBGN stimulation increased collagen release. Each 
dot represents one sample. Shown are mean values (± the standard deviation [SD]) from 6 independent 
experiments (using samples obtained from 6 different biological donors). Samples were measured as technical 
duplicates and averaged. *p<0.05 vs. non-stimulated controls. #p<0.05 for pairwise comparisons between mild 
grade I OA and severe grade IV OA. 
As demonstrated by the results presented in Figure 24, the TLR4 expression is increased in OA 
cartilage as disease severity increases. Most likely this is due to the continuous release and 
accumulation of endogenous ligands emanating from articular cartilage degradation such as 
fibronectin, hyaluronan as well as sBGN. Therefore, we studied the effect of sBGN on the mRNA 
expression of TLR2 and TLR4, find out whether sBGN has the ability to regulate TLR2 and 4 expressions. 
In primary OA chondrocytes sBGN increased TLR4 mRNA expression significantly while TLR2 mRNA 
expression remained much unchanged. In line with previous results, cartilage explant TLR-response to 
sBGN was dependent on the grade of cartilage degradation. TLR4 expression was upregulated by 
about 3 folds in sBGN-stimulated grade I OA explants in comparison with the response observed in 
grade IV OA explants (Figure 24). Blocking of TLR4 by using a small molecular weight inhibitor of TLR4 
signaling, CLI095, abrogated both sBGN and LPS induced upregulation of TLR4 mRNA expression in 
primary chondrocytes (Figure 24).  
Figure 24. Effects of soluble biglycan (sBGN) on the TLR4 mRNA expression levels in primary chondrocytes and 
cartilage explants. (A) In primary chondrocytes, sBGN caused a significant increase on TLR4 expression to the 
same extent as LPS. The TLR4 upregulation was inhibited by CLI095, a synthetic inhibitor of TLR4 signalling. (B) 
In cartilage explants, sBGN stimulation caused a significant increase of TLR4 in grade I OA explants. Samples were 
run as technical duplicates, and each experiment was done using samples obtained from at least 6 different 
donors (biological replicates). All results are expressed as mean and SD *p<0.05, **p<0.01 vs. non-stimulated 
controls or pairwise comparisons. 
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The same effect was observed in a HEK-blue TLR4 reporter cell line used as control, where pre-
incubation of CLI095 before sBGN lead to a much lower level of SEAP, the reporter gene of NF-kB 
activity mediated by TLR4 activation (Figure 25). Further blocking studies demonstrated that sBGN 
proinflammatory effects, measure by the synthesis of NO species were mainly mediated in primary 
chondrocytes via TLR4 (Figure 26). 
 
Figure 25. Effects of soluble biglycan (sBGN) on HEK-blue TLR4 NF-kB reporter gene SEAP production. SEAP assay 
was used to determine NF-κB activity following sBGN, sDCN or LPS stimulation of human HEK-blue TLR4 reporter 
cells.  Lipopolysaccharide (LPS) was used as a positive control. The addition of polymyxin B had no effect on the 
sBGN-induced SEAP production while proteinase K restored SEAP production to levels seen in controls, further 
confirming no endotoxin contamination of sBGN. Results are from 3 independent experiments. All results are 
expressed as mean and SD. ***p<0.001 vs. non-stimulated controls. 
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Figure 26. Effects of soluble biglycan (sBGN) on chondrocyte production of nitric oxide (NO) compared to control 
groups. (A) In primary chondrocytes, sBGN stimulation caused an increase in NO production release to cell 
culture supernatant. Lipopolysaccharide (LPS), used as a positive control, induced a similar effect on NO 
production albeit the production levels were higher than during sBGN stimulation. (B) In cartilage explants sBGN 
stimulation led to a marked increase NO production in grade I osteoarthritis (OA), while in grade IV OA the 
differences were not substantial. (C) The addition of polymyxin B had no effect on the sBGN-induced NO 
production while proteinase K restored NO production to levels observed in control groups, strongly suggesting 
endotoxin contamination of sBGN was not present. The addition of TLR2 neutralizing antibody caused no 
significant alteration of sBGN-induced NO production levels while TLR4 neutralization impaired NO production. 
Samples were run as technical duplicates, and each experiment was done using samples obtained from at least 
six different donors (biological replicates). All results are expressed as mean and SD. ***p<0.005 vs. non-
stimulated controls or pairwise comparisons. 
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6. Discussion 
6.1. Primary vs. differentiated MSC-derived chondrocytes: TLR1/2 heterodimer response 
Our results demonstrated that TLR1, TLR2 and TLR9 were expressed in mature chondrocytes but also 
in MSC differentiated for 21 days to chondrocytes at mRNA and protein level. Together these findings 
may settle the apparent discrepancies in some previous studies, which did not report TLR1 and TLR9 
protein expression and contradictory results of their mRNA expression levels (156,226,227). 
In this study, we used primary chondrocytes and MSC-derived chondrocytes cultured for 21 
days to study the innate immune response capacity of MSC-derived chondrocytes, given their active 
use and potential for cell therapy applications of cartilage regeneration in OA joints. Interestingly our 
study revealed that TLR-profile is altered during the activation and differentiation stage of 
chondroprogenitors. As results show TLR1, TLR2 and TLR9 were mostly upregulated in primary OA 
chondrocytes and chondroprogenitors (day O) but were weakly expressed in healthy MSC-derived 
chondrocytes cultured for 21 days. 
TLR1/2 heterodimer activation by Pam3CSK4 was studied given that TLR1 and TLR2 had high 
expression levels in trauma-derived primary chondrocytes. Heterodimer activation was studied 
instead of TLR2 homodimer given that the latter has been already studied in chondrocytes (259). The 
results demonstrated that TLR1 and TLR2 are functionally active in human chondrocytes (Pam3CSK4 
ligand stimulation) in heterodimer TLR1/2 form. Importantly, danger signal-TLR1/2 interaction led to 
a significant up-regulation of the proinflammatory cytokine TNF-α, but also of TLR1 and TLR2 
expression. 
Because Pam3CSK4 caused significant increase in levels of TNF-α in trauma-derived primary 
chondrocytes, its local effects were studied, since a local production by chondrocytes could act in an 
autocrine manner and, therefore, might have a pathophysiological role in OA, as proposed by others 
(260,261). Chondrons contain more than one cell and thus chondrocyte production of TNF-α could 
have juxta and paracrine effects on other chondrocytes (262). Such stimulation revealed interesting 
results. TNF-α lead to upregulation of TLR2 levels in a dose-dependent manner. TLR1 and TLR9 mRNA 
levels were mostly unchanged and not statistically significant. This effect was surprising and 
unexpected with only similar reports in inflammatory cells such as macrophages, microglia or fist-line 
defense pleural mesothelial cells (PMCs) (263-265). Also, we demonstrated that TNF-α stimulation 
also caused self-upregulation of mRNA levels in primary OA chondrocytes. 
By studying proteoglycan deposition with Safranin-O staining, we could observe the effects 
TNF-α-stimulation caused on newly formed ECM in pellets from MSC-derived chondrocytes cultured 
for 21 days. TNF-α-stimulation caused a major depletion of PGs in a dose-dependent manner. In line 
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with observed proteoglycan depletion, TNF-α-stimulation caused a marked increase of COL2A-3/4M 
immunostaining, hence an increase in collagen type-II cleavage in the ECM of pellets from MSC-
derived chondrocytes cultured for 21 days. The observation of proteoglycan depletion and collagen 
cleavage is typical. Proteolytic enzymes degrade cartilage ECM cartilage by disrupting ECM PGs to 
which may follow collagen cleavage and degradation (266). 
As mentioned earlier TNF leads to the upregulation of TLR2, but not TLR1 or TLR9. It will be 
interesting to study further its effects on the remaining TLRs. The results open new questions about 
the role of other OA relevant cytokines in the innate immunity mediated inflammation in OA and their 
role in TLRs expression and signalling. Critical OA cytokines such as IL-6, GM-SF and IL-17 have already 
been shown in other cells to regulate the expression of TLR2 and TLR4, TLR3 and TLR7, and TLR3 
respectively (267-269). 
Taken together these results suggest that TLR1, TLR2 and TLR9 in OA chondrocytes not only play 
some homeostatic maintenance role but may be actively involved and differentially regulated during 
OA inflammation and chondroprogenitor differentiation. We also demonstrated that in chondrocytes 
TNF-α stimulation, a potent proinflammatory cytokine present in OA, also leads to chondrocyte TLR2 
activation. Together TNF-α and TLR2 activation mounted an inflammatory response sufficient to 
compromise the integrity of native PGs and collagen in new cartilage ECM synthesised by MSC-derived 
chondrocytes. 
Our results should be considered in the current strategies utilizing MSCs as novel treatment- 
and regenerative therapy efforts in the OA field. Our research demonstrated that if in the OA joint 
inflammatory environment elements such as cytokines or DAMPs are not neutralized, they can affect 
and degrade newly synthesized ECM by MSC, even despite MSCs known anti-inflammatory properties.  
6.2. TLR expression during OA progression in knee and CMC-I joints 
In our previous study, we demonstrated that TLR1, TLR2, and TLR9 were present in articular cartilage 
from trauma patients, and their ability to be activated and initiate a cartilage degrading response. 
However, in the OA joint several more other cytokines and DAMPs are present, and in higher 
concentrations, which can further activate other TLRs. Therefore, it is important also to expand our 
knowledge to include the full list of TLRs, and how their expression is regulated during progressing 
degradation of OA cartilage. Moreover, in the current study we were also interested in studying TLRs 
expression in smaller joints such as the CMC-I given its different size, biomechanical loading, and 
different risk factors. 
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Our results demonstrated that human articular cartilage resident chondrocytes in the surface 
zone were fully equipped with all TLRs even at early stages of OA (OARSI grade I). Our results also 
indicate that TLR expression in cartilage may start at the surface zone and that TLR signalling of 
chondrocytes in deeper layers become activated later. These findings seem to fit in the current 
conceptual mechanisms of OA pathogenesis since it is at the surface zone where initial wear and tear 
occurs and where the surface fibrillation and focal loss of cationic staining (proteoglycan loss) are first 
seen (87). Therefore, resident chondrocytes at this location are the first line responders to the 
released ECM degradation, also known as danger signals, able to trigger the danger signal receptors 
namely the TLRs. At OARSI grade 2, the proportion of TLR-positive cells further increases but also 
extends into the middle zone of cartilage. At OARSI grade 3 and 4, the TLRs expression reach highest 
proportions. Surprisingly, such level of expression corresponds with the peak of extensive cartilage 
degradation. At this levels cartilage fissure extends up to the deep zone, and 2/3 of cartilage is 
proteoglycan depleted. Interestingly, it is also at this level where one may expect the highest peak of 
cartilage degeneration and release of danger signal at highest concentration levels, due to 
accumulation as well. These results are in line with a similar pattern only studied for TLR4 using an 
equivalent histological scoring [11]. It is also tentative to speculate that this proportion of TLR positive 
chondrocytes is congruent with the severity and topology of cartilage damage, maybe being a way to 
adjust the degree of TLR-mediated proinflammatory response in chondrocytes during the disease 
development. 
In contrast, with the consistent increase in the expression of TLRs as the disease process of 
knee OA progresses through cartilage layers (OARSI grade definition), the TLR expression pattern in 
cartilage from CMC-I OA was substantially different.  
Given the heterogeneous CMC-I histomorphometric data, we applied principal component 
analysis (PCA) in order to discover if protein-expression patterns were present thereby allowing easier 
interpretation. PCA revealed a clear clustering of TLRs which can form heterodimeric complexes at the 
surface of the cell (TLR1, 2, 5 and 6), in parallel with the clustering of the endosomal TLRs (TLR7, 8 and 
9). In general, all these MyD88-dependent TLRs co-operate with each other (170). The only exception 
was TLR3 clustering with the cell surface TLRs. Unlike the previously mentioned TLRs, TLR3 does not 
use MyD88 but uses a TRIF-dependent signaling pathway exclusively. Nevertheless, the association 
with surface TLRs such as TLR2 might have functional consequences because they have synergistic 
proinflammatory effects mediating a “two-hit” trigger (270). Interestingly TLR4 acted unequivocally 
differently compared to other TLRs. It is worth in this context to note that TLR4 is the only TLR using 
both MyD88 and TRIF signaling. TLR4 protein expression constantly remained  low across all CMC-I 
samples in a striking contrast to the increased expression in knee OA disease progression. 
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Our study shows conclusively that all TLRs are actively expressed in knee OA cartilage which 
settles the debate about their expression in chondrocytes from knee cartilage origin 
(157,226,227,271). However, we observed differential expression of TLRs in OA cartilage which 
depended on the joint in question. Reasons contributing to such differences may relate to the 
common and independent factors known to be associated with hand and knee OA joints. Risk factors 
such as obesity, for example, may be involved. Obesity is known to increase the likelihood of hand OA 
by two-fold (272). However, given that mechanical overload does not affect non-weight-bearing joints 
such as hand OA, other obesity-related systemic factors such as adipokines may be involved 
(28,273,274). Adipokines are not only present systemically but are also present in OA joint SF in 
significant concentrations (275). Adipokines have been shown to have anti- and proinflammatory 
properties but also shown to regulate TLR expression and vice-versa (276,277).  
Genetic and epigenetic differences between the two joints may also play a significant role in 
in the substantially different TLR expression. As OA is a polygenic disease, recent genome-wide 
association study (GWAS) efforts have identified several risk-conferring loci for hip, knee and hand 
OA. This information also showed that certain loci only associate with certain joints, further stressing 
the need for joint stratification when studying OA (278-280). Interestingly TLR3 and TLR9 
polymorphisms are associated with end-stage knee OA (281,282). TLR polymorphisms associated with 
other OA joints, such as hand OA remain to be studied.  
Dilution of cartilage matrix-derived danger signals (damaged/solubilized ECM) may also differ 
significantly. It has been known for some time that knee joint SF clearance depends on the disease 
type and stage (139). However, it remains to be studied if clearance kinetics of SF in other joints, differ 
from the finding in the knee joint. Different SF clearance rates would clearly affect local concentrations 
of potent TLR-activators such as cytokines and DAMPS and could underline our current observation of 
differential TLR expressions between CMC-I stages and CMC-I and knee OA cartilage. Other intrinsic 
differences may also play a role such as biomechanical loading (macro vs. micro), anatomy and joint 
size. 
Epidemiological associations between hand OA and other OA joint incidence have been 
intensely studied, and many associations have also been found. Nevertheless, to date, few studies 
have confirmed extensive common pathomechanisms occurring in OA joint (283,284). Our findings at 
this early stage suggest that the expression of TLRs is inherently different between knee and CMC-I 
OA joint, which also would suggest significant differences in the innate immunity mechanisms driving 
OA in different joints. 
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Our results add an extra piece of evidence to the current literature such as the epigenetic and 
transcriptomic studies stressing that the “disease process” of OA is unlikely to be uniform across the 
synovial joints of the body (283,284). 
6.3. The role of SLRPs in OA 
BGN and DCN are two major SLRPs embedded into the cartilage ECM matrix known to be maintained 
by articular chondrocytes (285). In the current study, we demonstrated, to our knowledge, for the first 
time, that sBGN and sDCN native forms are present in SF collected from patients with meniscectomy, 
TKA due to advanced OA stage or RA. Interestingly the highest concentration levels of sBGN are found 
in SF from advanced OA and RA patients. The concentrations of intact sDCN, in contrast to sBGN, were 
relatively low and constant across meniscectomy, in advanced OA-, and RA patients. The presence of 
sBGN in SF implies that chondrocytes, as well as other resident cells in joint tissues, may be in contact 
with the fluid phase of sBGN and sDCN.  
The measured concentration levels of intact soluble sBGN are in congruence with the reported 
up-regulation of gene and protein expression levels of sBGN in human OA cartilage and as well with 
reported levels in sheep cartilage, obtained from a sheep meniscectomy model of OA. Although BGN 
and DCN are closely related and follow the same trend of increased gene and protein expression, the 
levels of DCN remain unchanged and in striking contrast with measured BGN levels in SF 
(245,286,287). Despite the close structural relationship shared by these two SLRPs, several studies 
have shown they compete for same bindings sites but also bind to different sites and are differentially 
cleaved by proteolytic enzymes. It is, therefore, tempting to speculate that these may well be 
explanatory factors for the different concentrations of intact BGN and DCN in SF (288,289). 
Intact sBGN and sDCN, but not their fragment forms, have been shown to engage 
proinflammatory responses (244,290). BGN fragments have been shown to be increased in cartilage 
of OA patients, and to be released from cartilage explants in in vitro studies. Hence, the presence of 
sBGN fragments is a reflection of disease activity, without further molecular implications being mostly 
suited for diagnostic biomarker applications. Interestingly, SF from OA and RA patients is known to 
contain BGN, DCN, and other cartilage  IgG autoantibodies of matrix molecules, indicating SLRPs 
release from cartilage matrix and subsequent local loss of immunological tolerance (291). Immune 
complex formation leading to complement and FcγR activation plays a role in RA, but according to 
recent studies also in OA (292-294). The present finding of intact sBGN in SF, together with the 
recognition of sBGN as a DAMP-type ligand for TLR2/4 and P2X7/4, provides a third mechanism of 
relevance for autoinflammation, co-stimulation, and autoimmunity. 
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Elsewhere in this thesis, it was demonstrated that in knee OA the resident cartilage 
chondrocytes express all known TLRs, including sBGN ligand receptors TLR2 and TLR4, and that as the 
disease progresses also the proportion of TLR+ chondrocytes increases. In our most current study, we 
demonstrated that sBGN was able to regulate TLR4 expression in a similar fashion as the potent 
activator LPS used as a positive control. We further confirmed that such observation was not caused 
by the sBGN isolation process since endotoxin tests were negative and sBGN incubation with 
polymyxin B did not alter the measured response in OA primary chondrocytes. These results were 
further confirmed in a parallel experiments using HEK-blue TLR4 reporter cell line. Together these 
were strong indicators that sBGN, derived from articular cartilage, could in fact act as a DAMP. 
Moreover, we were also able to determine that the sBGN mechanism of action proceeded through 
TLR4 activation and the NF-κB pathway. Using a human HEK-blue TLR4 reporter cell line, which only 
expresses TLR4, we showed that sBGN and sDCN stimulations caused upregulation of AP production, 
as a result of increased activation of the reporter gene SEAP monitoring NF-κB activation. Also, AP 
production was halted by CLI095 incubation, which is a synthetic inhibitor of TLR4 signaling. NF-κB 
activation by sBGN was further confirmed in primary OA chondrocytes by studying NO production and 
release to cell culture medium. TLR4 signaling in chondrocytes is mediated through NF-κB, and NF-κB 
activation is the major inducer of iNOS (295,296). Moreover, NO is a proinflammatory molecule at 
increased levels in OA synovial fluid and is an active contributor to the inflammatory mechanism of 
OA (297-299). sBGN stimulation leads to increased NO concentration levels in supernatant medium 
from in primary chondrocyte cultures while sBGN incubation with CLI095 or TLR4 neutralizing antibody 
restored NO to baseline concentration levels. Interestingly TLR2 neutralizing antibody did not have 
any effect on the sBGN-induced increased production of NO. Taken together the observed increase of 
secreted AP and NO in our cell culture studies, strongly suggested that sBGN can mount a 
chondrocyte-mediated inflammatory response. 
The sBGN concentrations used in our in vitro experiments were significantly higher than those 
measured in SF from OA patients, and may well be a limitation in our research. Nevertheless, in earlier 
in vitro experiments, sBGN stimulation exerted dose-dependent effect up to 20 fold concentration 
levels (300). In addition, BGN is mainly localized at cartilage pericellular matrix where it is most likely 
found at much higher concentrations than in SF (301). Moreover, sBGN was used at higher 
concentrations to assure outside-in access since in our in vitro experiments cartilage explants lacked 
native biomechanically cyclic compression which causes a decrease in interstitial fluid pressure. Thus, 
we expect the used sBGN concentrations of 10 fold higher than those found in SF, to be most likely of 
pathophysiological relevance.  
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sBGN stimulation of primary chondrocytes caused an upregulation of known OA-related 
proteolytic enzymes at the mRNA and protein level (302). The fact that sBGN caused upregulation of 
ADAMTS-4/5, MMP-9, MMP-13 and cathepsin-k means that all the main structural elements of 
cartilage matrix can be degraded indicating that cartilage integrity can be compromised by sBGN-TLR4 
activation. Stimulation of chondrocytes with sBGN also caused an increase of production of 
proinflammatory cytokines IL-6 and IL-8. Their active release into the synovial joint could then lead to 
recruitment and inflow of neutrophils and macrophages (303,304). The sBGN induced induction of 
MMPs and proinflammatory cytokines could add further stress to the OA joint and might contribute 
tilting the balance towards continuous inflammation and perpetuating cartilage degradation. 
Our current study also demonstrated that the respone of OA cartilage explants to sBGN was 
clearly dependent on the macroscopic grade of OA. We observed a substantially higher sBGN-induced 
TLR4 upregulation in grade I OA in comparison to grade IV OA. Interestingly, BGN and TLR4 are more 
upregulated in advanced stages of OA when compared to early stages (245). This suggests that 
desensitization to BGN  but also TLR4 impaired function in grade IV OA explants may have occurred 
due to long-term exposure to sBGN and other known DAMPs at this end stage. However, negative 
regulatory mechanisms and functio laesa due to long-term exposure and chronic inflammation should 
also not be excluded as possible reasons. Thus, in grade I OA, the sBGN induction of high TLR4 
expression leads to significantly higher levels of MMPs and ADAMTS as well as NO release to 
supernatant. 
Stimulation with sBGN also inhibited the synthesis of collagen type II and aggrecan which are 
two essential structural elements of cartilage matrix. The sBGN effect on this two matrix elements was 
also dependent on the grade of cartilage explants, with the highest inhibition occurring in grade IV OA 
explants. The resulting imbalance between de novo synthesis and matrix degradation will then lead to 
a net loss of cartilage matrix elements and compromise of cartilage integrity (305,306). 
Given the high efficiency and consequences of enzymatic activity, the proteolytic activation of 
cartilage degrading proteases is highly regulated. It is, therefore, no surprise that at the core of known 
pathomolecular mechanism of OA lies the proteolytic activation of aggrecanases and collagenases to 
which we have shown that sBGN stimulation was able to contribute. In the current study, we 
demonstrated the increased production and released of ADAMTS, MMPS, and cathepsin-k, which are 
known for their ability to degrade structural cartilage molecules. In addition, we also demonstrated 
the final product of their activity, measured by the release of PGs and collagen degradation products. 
By measuring the release of PG using a dye-based glycosaminoglycan assay we determined that sBGN 
stimulation caused sharper increased release of PGs in grade I OA vs. grade IV OA much in line with 
the observed higher production and release of cartilage degrading proteases. Collagen release was 
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also determined by dye-based collagen assay, however, and in contrast to PG release results, collagen 
release to the supernatant medium was only significantly different in type IV OA. This may be due to 
an already advanced stage of PG depletion which, allows better access to collagenolytic enzymes to 
degrade collagen fibers (266). 
7. Conclusions 
This study focuses on the role of chondrocytes and chondroprogenitors in OA inflammation, especially 
in terms of cartilage degradation, TLR expression, the response of chondrocyte cells to 
proinflammatory cytokines and newly identified DAMPs, and the production of proinflammatory 
cytokines, cartilage degrading enzymes and ECM molecules. Our main findings can be summarized as  
follows: 
1. TLR1, TLR2 and TLR9 expression was confirmed in trauma-derived primary 
chondrocytes, articular cartilage, and chondroprogenitors. We demonstrated that 
during chondrocyte differentiation the initial high expression of TLR1, 2 and 9 
decreases towards baseline levels in fully differentiated chondrocytes.  
2. We demonstrated that the proinflammatory cytokine TNF-α is able to increase the 
expression of TLR2 in both healthy primary chondrocytes and in MSC-derived 
chondrocytes for 21 days. TNF-α was demonstrated to induce cartilage degradation 
in de novo ECM matrix from pellet cultures of MSC-derived chondrocytes cultured for 
21 days. This implicates TNF-α as an inducer of matrix degradation, with wide possible 
implications when using MSCs strategies in cartilage repair strategies for OA.  Our 
study also added further evidence for a role of TNF-α in inducing TLR-innate immunity 
in the OA synovial joint. 
3. TLR protein expression in cartilage from knee and CMC-I OA patients was shown to be 
strikingly different. Our study demonstrated, for the first time, all known TLRs being 
expressed at protein level in cartilage of knee OA patients. Moreover, we 
demonstrated that their expression is up-regulated in a cartilage zone-dependent 
fashion according to the histological progression of knee OA. Expression of TLRs in 
cartilage from CMC-I OA patients was highly heterogeneous, although it followed an 
close expression pattern according to the known TLR cell compartment localizations 
This study implicates that TLR mediated innate immune response in the two joints 
may be significantly different. 
4. Decorin, a known SLRP, and a ligand able to activate TLR2 and TLR4, was for the first 
time shown to be present in knee synovial fluid of both OA and RA patients. We 
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confirmed the ability of sDCN to activate TLR4 signaling. However, the observed low 
and stable concentration levels across the studied arthritis groups mean that these 
findings may not be of clinical relevance in OA pathogenesis and the associated TLR-
mediated inflammatory events. 
5. Biglycan, another known SLRP ligand able to activate TLR2 and TLR4, was for the first 
time found to be present in knee synovial fluid of OA and RA patients. Interestingly 
we discovered that sBGN is upregulated in synovial fluid from OA and RA patients. The 
ability of sBGN to activate TLR-mediated innate immunity was shown to be mediated 
through TLR4 signaling. The sBGN stimulation leads to upregulation and release of 
proinflammatory cytokines, matrix-degrading enzymes and the release of ECM 
degradation products. 
 
As a final conclusion we believe TLRs to be potentially important drivers in the synthesis of 
proinflammatory and destructive enzymes associated with OA.  Our results together with extensive 
evidence from the literature point towards a prominent role of TLRs in OA. TLR activation could be 
initiated as a proinflammatory reaction against cartilage matrix degradation products which may be 
accumulated into synovial fluid due to low synovial fluid clearance and the avascular and alymphatic 
nature of articular cartilage. As results of TLR activation in joint tissue cells, proinflammatory, 
proteolytic enzymes and algogenic secondary mediators are released, which then may further 
compromise cartilage structure, upregulate TLRs, and activate infiltration of inflammatory cells to the 
synovium leading to secondary synovitis and pain (307,308). Such close regulation may likely 
orchestrate the rate and severity of the OA joint tissue catabolism and degradation. Figure 27 
illustrates the conceptualization of TLR innate immunity role in the perpetuating cycle of OA disease. 
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Figure 27. Conceptualization of the Toll-like receptors importance in the perpetuating circle of cartilage 
degradation and inflammation that characterize the pathogenesis model of osteoarthritis.  
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